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Matthew 7:7 “Ask, and it will be given to you; seek, and you will find; knock, and 
it will be opened to you.” 
     
  
ABSTRACT 
Obesity is a major health concern across the globe and is often associated with insulin 
resistance and type 2 diabetes. The coupling of energy intake and expenditure is tightly 
regulated by central and peripheral mechanisms and is dysregulated in obesity. This 
thesis focuses on the role of central and peripheral mechanisms regulated by signaling 
via the leptin receptor and AMP-activated protein kinase (AMPK) in regulating energy 
and glucose homeostasis. 
Leptin signaling through the long form of the leptin receptor (LepRb) plays a role 
in the regulation of glucose and energy homeostasis. Leptin action is mediated by 
phosphorylation of several tyrosine residues on LepRb, of which Tyr985 plays a major 
role. The aim of Study I was to elucidate the role of LepRb-Tyr985 in glucose 
metabolism. LepRb-Tyr985 mutant mice (l/l mice) that lack feedback inhibition of 
LepRb signaling had improved glucose tolerance and insulin sensitivity. Euglycemic-
hyperinsulinemic clamp studies performed in l/l mice revealed enhanced hepatic and 
peripheral insulin sensitivity. Thus, LepRb-Tyr985-mediated signals regulate whole-
body glucose metabolism and insulin sensitivity. 
Tissue-specific alterations in mitochondrial respiration have been implicated in 
obesity and type 2 diabetes. The aim of Study II was to determine the role of leptin in 
regulating tissue-specific mitochondrial respiration in obese leptin-deficient ob/ob 
mice. Hepatic mitochondrial respiration was reduced in ob/ob mice and unaltered by 
short-term leptin treatment. Mitochondrial electron transport capacity was enhanced in 
glycolytic extensor digitorum longus (EDL) muscle, whereas mitochondrial function in 
oxidative soleus muscle was unaltered by obesity or leptin treatment in ob/ob mice. The 
present study highlights the tissue-specific mitochondrial adaptations imposed by 
obesity and its modulation by short-term leptin treatment.  
AMPK is activated in response to cellular energy demand and turns on cellular 
processes that restore energy balance. Skeletal muscle overexpression of an activating 
form of AMPK (AMPKγ3
R225Q
) provides protection from high-fat diet induced insulin 
resistance. Study III was designed to test the hypothesis that skeletal muscle-specific 
expression of the AMPKγ3
R225Q
 isoform rescues the metabolic abnormalities associated 
with leptin deficiency in ob/ob mice (ob/ob-γ3
R225Q
). The AMPKγ3
R225Q
 mutation 
confers favorable metabolic adaptations including increased skeletal muscle glycogen 
content and decreased intramuscular triglyceride content, but glucose tolerance and 
skeletal muscle insulin-stimulated glucose uptake was unaltered. This implies that 
central defects arising from leptin deficiency overrides many of the positive benefits 
brought about by peripheral AMPK signaling.  
Collectively, the results presented in this thesis highlight the role of leptin 
receptor and AMPK signaling in the regulation of glucose and lipid metabolism from a 
whole-body perspective. Strategies targeted at improving leptin sensitivity and skeletal 
muscle-specific AMPK activation open up new venues for the treatment of metabolic 
complications associated with diabetes and obesity. 
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1 INTRODUCTION 
Obesity is derived from the Latin word “Obesus” meaning fat. There is a rapid increase 
of obesity worldwide. The World Health Organization defines overweight and obesity 
as a condition in which abnormal or excessive fat accumulation poses a health risk 
(WHO-report 2000; Ofei 2005). Body mass index (BMI) which is the ratio of body 
weight in kilograms to the height in meter square defines the border that determines 
whether a person is underweight (BMI <18.5 kg/m
2
), normal (BMI 18.5-24.9 kg/m
2
), 
overweight (BMI 25-29.9 kg/m
2
) or obese (BMI >30 kg/m
2 
(WHO-report 2000). The 
caveat with BMI is that it neither takes into consideration whether the weight is 
predominantly attributed to fat or lean mass nor the distribution of the fat mass. 
Another more reliable and accurate way to measure adiposity is by calculating the waist 
to hip ratio (Kissebah et al. 1994). As the prevalence of obesity is increasing 
dramatically, efficient treatment strategies for the prevention and treatment need to be 
developed. 
 
Obesity is often associated with metabolic abnormalities. The excess accrual of visceral 
fat acts as an endocrine tissue, secreting a variety of hormones and cytokines that can 
trigger metabolic abnormalities across various organ systems, which conglomerate and 
bring about the metabolic syndrome. The metabolic syndrome is a cluster of metabolic 
complications (dyslipidemia, hypertension, dysregulated glucose homeostasis, visceral 
adiposity and insulin resistance) that increases the risk of coronary heart disease and 
type 2 diabetes (Alberti et al. 1998; Zhu et al. 2002; Kassi et al. 2011). Obesity also 
predisposes a person to develop stroke, osteoarthritis and certain types of carcinomas 
(uterus, ovaries, breast, colon, rectum and prostate) (Aleksandrova et al. 2013; Esposito 
et al. 2013; Olsen et al. 2013; Rundle et al. 2013). Understanding the etiology and 
development of obesity can shed light into the development of effective strategies that 
can bring down the rate and rise of obesity and its associated comorbidities. 
 
Obesity mainly results from an imbalance of energy intake and expenditure. Excess 
energy that is not immediately required is stored in the form of glycogen and 
triglyceride for later use (Owen et al. 1979). The coupling of energy expenditure and 
energy intake is a tightly regulated process that is brought about by interaction between 
different organ and hormonal systems. The central nervous system (CNS) plays a 
crucial role by acting as a master regulator, integrating signals from the periphery and 
regulating metabolic processes to ensure optimum energy balance of the organism. 
When there is a persistent mismatch between energy intake and energy expenditure, 
there will be weight gain in the form of fat accumulation if the organism is in positive 
energy balance and weight loss if there is a negative energy balance. Persistent positive 
energy balance leads to obesity (Stanhope et al. 2008; Kelly et al. 2009).  
 
1.1 OBESITY AND INSULIN RESISTANCE 
Obesity and insulin resistance are closely connected and the constellation predisposes 
for type 2 diabetes and associated metabolic complications. Obesity is often associated 
with a dysregulation of endocrine, neural and inflammatory pathways that contribute to 
the development of insulin resistance. Insulin resistance is defined as a condition in 
which normal insulin levels elicit a subnormal biological response in insulin-sensitive 
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tissues such as skeletal muscle, adipose tissue and liver (Lima et al. 2002). In insulin 
resistant conditions, insulin-stimulated glucose uptake is compromised in skeletal 
muscle and adipose tissue with concomitant defects in the suppression of hepatic 
glucose production. Understanding the molecular pathways of insulin signaling is 
important to bring about appropriate therapeutic interventions to treat metabolic 
disease. 
 
Metabolic perturbations associated with obesity affect the insulin signaling cascade in 
insulin-sensitive tissues. Binding of insulin to the insulin receptor (IR) leads to auto-
phosphorylation of the tyrosine residues and a conformational change of the receptor 
(White et al. 1994). This allows the insulin receptor substrate (IRS) proteins to interact 
and associate with the IR, and in turn undergo phosphorylation (Sun et al. 1991). 
Phosphorylated IRS allows Src-homology-2 domain (SH2 domain) containing 
molecules to bind to phosphorylated tyrosine residues on IRS (White 1998; Virkamaki 
et al. 1999). The SH2 domain containing enzyme phosphoinositide (PI) 3-kinase 
interacts with phosphorylated IRS and in turn activates Akt/PKB (protein kinase B), 
which is a key molecule regulating insulin-mediated metabolic actions (Cross et al. 
1995; Kohn et al. 1996; Harris et al. 2003). Insulin-stimulated glucose uptake in 
skeletal muscle accounts for 75% of glucose metabolism in the postprandial state 
(DeFronzo 1988; Zierath et al. 1998; DeFronzo et al. 2009). Under insulin-stimulated 
conditions, Akt is phosphorylated in skeletal muscle. Akt phosphorylates and 
inactivates the Akt substrate of 160 kDa (AS160), which in turn leads to translocation 
of glucose transporter (GLUT) 4 to the plasma membrane, and facilitates glucose entry 
to the cell (Karlsson et al. 2005; Larance et al. 2005; Miinea et al. 2005) (Fig 1). In 
parallel, Akt also stimulates glycogen synthesis in skeletal muscle. The ability of 
skeletal muscle to take up glucose in response to insulin is critical for the maintenance 
of glucose homeostasis and is blunted in conditions of insulin resistance (DeFronzo et 
al. 1982; DeFronzo et al. 1985; Zierath et al. 1998).  
 
In liver, insulin signaling has a crucial role in the regulation of hepatic glucose 
production and lipogenesis. In response to insulin stimulation, phosphorylated Akt 
inactivates forkhead transcription factor 3, which results in decreased expression and 
activity of gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase (G6Pc), which suppress hepatic glucose production (Matsuura 
et al. 1975; Haeusler et al. 2010; Zhang et al. 2012). At the same time, hepatic insulin 
signaling stimulates lipogenesis via Akt, and regulates the expression of a key lipogenic 
gene namely sterol regulatory element-binding protein-1C (Foretz et al. 1999; 
Fleischmann et al. 2000; Ono et al. 2003; Leavens et al. 2009). In insulin resistant 
states, the ability of insulin to suppress hepatic glucose production is blunted 
(DeFronzo et al. 1982).  
 
In adipocytes insulin stimulates glucose uptake via GLUT4 and favors lipogenesis with 
concomitant suppression of lipolysis. Insulin suppresses the activity of the rate limiting 
lipolytic enzyme, hormone sensitive lipase, thereby inhibiting lipolysis (Anthonsen et 
al. 1998; Kitamura et al. 1999). Insulin resistance in adipose tissue is accompanied by 
defective suppression of lipolysis resulting in increased circulating free fatty acid levels 
further leading to insulin resistance in other tissues (Landin et al. 1990; Magkos et al. 
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2012). Defects in the insulin signaling cascade affect multiple tissues and contribute to 
the metabolic derangements associated with obesity. 
 
In obesity, visceral adipose tissue hypersecretes proinflammatory adipokines and free 
fatty acids, which affect hepatic and peripheral insulin sensitivity and ultimately lead to 
hyperglycemia. Increased levels of circulating fatty acids can compete with glucose for 
oxidation and consequently reduce insulin-stimulated glucose uptake in the peripheral 
tissues (Randle et al. 1963; Shulman 2000; Hue et al. 2009). Fatty acid metabolites 
such as diacylglycerol (DAG), ceramides and acyl-CoAs induce insulin resistance by 
activating protein kinases such as protein kinase C (PKC), c-Jun N-terminal kinase 
(JNK) and IKKB (inhibitor of nuclear factor-kappa B kinase-B) (Griffin et al. 1999; 
Samuel et al. 2004). These kinases increase serine phosphorylation of IRS and 
consequently reduce insulin signal transduction (Li et al. 2004). In addition to fatty 
acids, several lines of evidences suggests that elevated levels of adipokines including 
resistin, plasminogen-activator inhibitor-1 (PAI-1), interleukin (IL)-6, tumor necrosis 
factor (TNF)-α and retinol-binding protein (RBP) -4 can induce insulin resistance 
(Hotamisligil et al. 1993; Hotamisligil et al. 1996; Mitrou et al. 2011). Furthermore, 
adiponectin, which confers insulin sensitivity, is decreased in obese conditions (Stefan 
et al. 2002). These changes affect the ability of insulin to inhibit hepatic glucose 
production and stimulate peripheral glucose uptake in skeletal muscle and adipose 
tissue. Pancreatic β-cells hypersecrete insulin to compensate for the insulin resistance 
(Clark et al. 2001). When the β-cells of the pancreas fail to secrete enough insulin to 
overcome the insulin resistance, clinical manifestation of diabetes in the form of 
hyperglycemia ensues (Guillausseau et al. 2008). 
 
 
Figure 1: Glucose uptake in insulin-sensitive peripheral tissues. In insulin-resistant 
conditions, increased levels of FFA and intracellular lipid metabolites, along with 
proinflammatory cytokines, negatively affect the insulin signaling cascade. 
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1.2 ROLE OF THE HYPOTHALAMUS IN ENERGY METABOLISM  
Early studies of hypothalamic lesions in rats stress the role of the hypothalamus in 
regulating adipose tissue mass (Hetherington 1940). Bilateral symmetrical lesions in 
the ventromedial hypothalamic nuclei (VMH) resulted in substantial hyperphagia and 
consequently adiposity. The same lesions in the lateral hypothalamic area (LHA) led to 
complete absence of spontaneous eating (Anand et al. 1951). These hypothalamic 
lesions led to the conclusion that the LHA is a feeding center and the medial 
hypothalamic region, a satiety center (Anand et al. 1955).  
 
1.2.1 Hypothalamus and feedback control system 
Hypothalamic lesion studies in parabiotic rats suggested that body weight changes are 
sensed by the hypothalamus (Hervey 1959). Parabiosis is the surgical technique of 
anastomosing blood vessels of two animals of the same genetic background in such a 
way that exchange of blood occurs between the animals through the peritoneal 
capillaries. Hypothalamic lesions in one of the parabiotic pair led to hyperphagia and 
subsequent weight gain due to increased adiposity. This in-turn led to aphagia in the 
other animal in the pair and was thought to be mediated by changes in the levels of 
blood metabolites from the lesioned rat (Kennedy 1953). Parabiotic experiments carried 
out on genetically diabetic and obese db/db mice with normal mice recapitulated the 
results from parabiotic studies of rats with hypothalamic lesions. Parabiosis between 
db/db mice and lean mice resulted in decreased food intake in the lean mice (Coleman 
et al. 1969). These results underscore the concept of a circulating factor released in 
db/db mice that in turn signals the satiety center to regulate food intake in normal mice. 
Parabiotic studies on another genetically obese and diabetic mouse model (ob/ob mice) 
with lean mice did not affect food intake in both parabionts. In addition, when ob/ob 
mice were parabiosed with db/db mice, the ob/ob mice had reduced food intake. These 
experiments led to the conclusion that ob/ob mice have normal hypothalamic satiety 
centers that are responsive to a circulating factor secreted by the db/db mice (Coleman 
1973). These hypothalamic lesion studies in rats and parabiotic experiments in mice 
established the concept of a feedback system regulating food intake at the level of the 
hypothalamus (Fig 2). 
 
1.2.2 Lipostat theory and afferent signals to the hypothalamus 
The lipostat theory proposes that the CNS regulates body fat mass, and that the 
metabolized fat products circulating in plasma affect energy balance through 
hypothalamic interactions (Kennedy 1953). Later, a positional cloning approach was 
used to identify the product of the obese (ob) gene secreted from the adipose tissue. The 
ob gene encodes an adipose tissue messenger RNA of 4.5 kb with 84% amino acid 
sequence similarity between human and mouse and has the characteristics of a secreted 
protein. The ob/ob mouse strain has a nonsense mutation in codon 105 resulting in the 
expression of twenty-fold higher ob RNA levels which was associated with a non-
functional gene product resulting in increased mRNA levels as part of a possible 
feedback loop (Zhang et al. 1994). This data provides evidence to suggest that the 
adipose tissue mediated ob gene product is a signal to regulate the size of the body fat 
depot (Zhang et al. 1994). The ob gene product of 16 kDa was cloned, and protein was 
produced and administered to lean wild-type, ob/ob and db/db mice. Administration of 
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the isolated protein resulted in a reduction of both food intake and body weight in wild-
type and ob/ob mice, whereas db/db mice did not respond. This not only proved the 
endocrine hypothesis of the ob gene product, but was the first evidence for the 
biological action of the adipocyte-secreted hormone “Leptin”, rooted from the Greek 
word “Leptόs” meaning thin (Halaas et al. 1995). Several other candidate molecules 
were discovered and proposed to act as afferent signals to hypothalamus and mediate 
food intake and body weight. Among them glucose, free fatty acids and peptides like 
cholecystokinin, neuropeptide Y (NPY), corticotropin releasing factor (CRF) were 
evaluated, but none were not found to be involved in the long-term regulation of food 
intake and body weight (Arase et al. 1988; Kulkosky et al. 1988; Peikin 1989). Thus, 
adipocyte-derived leptin signals to the hypothalamus to regulate food intake.  
 
Figure 2: A: Hypothalamic lesion studies in rats highlight the importance of the hypothalamus 
in the regulation of food intake. B: Parabiotic experiments in mice underscoring the concept of 
integration of peripheral signals in the hypothalamus, thereby regulating food intake and energy 
expenditure. C: Integrated view of the regulation of energy homeostasis. 
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1.2.3 Neuropeptides and hypothalamic nuclei in energy balance 
Various neuropeptides in the hypothalamic circuitry are involved in the regulation of 
energy homeostasis. The reduction in body weight and food intake in response to 
intracerebroventricular (ICV) injection of leptin into the third ventricle of wild-type and 
ob/ob mice implies that one or more hypothalamic nuclei are target sites for leptin 
action (Campfield et al. 1995). Leptin acts in various hypothalamic nuclei (arcuate 
nucleus, paraventricular nucleus (PVN), VMH and LHA) to modulate the levels of 
neuropeptides in the hypothalamus to regulate energy homeostasis. 
 
1.2.3.1 Arcuate nucleus 
The arcuate nucleus contains both orexigenic (appetite-stimulating) and anorexigenic 
(appetite-suppressing) neurons that are responsive to leptin. Orexigenic neurons include 
the agouti related peptide (AgRP) and NPY expressing neurons. The most abundant 
and potent orexigenic neuropeptide NPY (Adrian et al. 1983) is co-expressed with the 
leptin receptor in the arcuate neuronal population, which suggests a role for leptin in the 
regulation of NPY (Hakansson et al. 1996; Mercer et al. 1996). NPY mediates 
orexigenic actions by signaling via G-protein coupled receptors (Y1 to Y5). The 
regulation of NPY expression by leptin was underscored through studies of ob/ob mice, 
where hormone supplementation reduced high expression levels of NPY, independent 
of changes in body weight (Wilding et al. 1993; Schwartz et al. 1996). High levels of 
AgRP mRNA in the arcuate nucleus of ob/ob and db/db mice suggest a possible role 
for leptin in its regulation (Shutter et al. 1997). Immunohistochemistry studies on 
mediobasal arcuate nucleus identified co-localization of AgRP and the leptin receptor 
neurons. Leptin treatment of ob/ob mice resulted in a substantial reduction of AgRP 
mRNA levels (Wilson et al. 1999). Furthermore, leptin blunted the fasting induced up-
regulation of AgRP in arcuate nucleus. This suggests that part of the anorexigenic 
response to leptin is mediated by reducing the orexigenic neuropeptides in the 
hypothalamus. 
 
Anorexigenic neurons in the arcuate nucleus constitute proopiomelanocortin (POMC) 
and cocaine and amphetamine related transcript (CART) expressing neurons. The 
hypothalamic POMC system is important for the regulation of body weight and energy 
homeostasis and mutations in the POMC gene lead to obesity (Comuzzie et al. 1997). 
Proopiomelanocortin neurons express POMC, which is proteolytically cleaved into α- 
melanocyte-stimulating hormone (α-MSH) and binds to melanocortin receptors 
(MC3/MC4) and mediates anorexigenic responses (Mountjoy et al. 1994; Harrold et al. 
1999). POMC gene expression is reduced with short-term food restriction and is 
restored by leptin treatment (Cheung et al. 1997; Cowley et al. 2001). Another 
anorexigenic neuropeptide that regulates feeding behavior is CART. CART is 
predominantly found in the dorsomedial part of the arcuate nucleus and is responsive to 
leptin. Food deprivation reduced CART mRNA levels in the arcuate nucleus and leptin 
treatment of ob/ob mice, which lacks CART expression, restored CART mRNA levels 
(Kristensen et al. 1998). These experiments in the hypothalamic arcuate nucleus 
suggest a role of leptin in the regulation of food intake by modulating anorexigenic 
neuropeptides.  
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1.2.3.2 VMH, LHA and PVN 
Leptin responsive neurons implicated in energy homeostasis are also present in the 
VMH, LHA and PVN. Conditional knock-out of leptin receptors in VMH neurons 
leads to the development of obesity (Bingham et al. 2008). Leptin action in LHA 
modulates the incentive to feed and decreases food intake and body weight (Leinninger 
et al. 2009). PVN has dense fenestration of NPY/AgRP neurons along with POMC 
expressing neurons. In response to leptin, α-MSH binds to MC-3/MC-4 receptors and 
antagonizes the action of NPY on food intake (Cowley et al. 1999). Thus, the action of 
leptin in VMH, LHA and PVN, along with the neurons in the arcuate nucleus plays a 
prominent role in the regulation of energy homeostasis and food intake. 
 
1.2.4 Leptin receptor signaling 
1.2.4.1 Leptin receptor 
The leptin receptor (LepR) belongs to class I cytokine family and is encoded by the db 
locus. Several splice forms of the receptor (LepRa, b, c, d and e) exists. LepRb is the 
long form of the receptor, which has a functional cytoplasmic domain (Tartaglia et al. 
1995; Chen et al. 1996; Lee et al. 1996). Among the different spliced forms, LepRe 
does not have cytoplasmic domain and forms a soluble receptor that has been 
implicated as a transport protein (Lee et al. 1996). The long LepRb form has conserved 
intracellular domains with sequence motifs important for binding of Janus kinase (Jak) 
and signal transducer and activator of transcription (STAT) that are involved in 
mediating intracellular signal transduction (Chen et al. 1996). 
 
1.2.4.2 Signaling through the long form of the leptin receptor 
Leptin receptor signaling is primarily mediated through LepRb. LepRb exists as a 
homodimer in the inactive state and has constitutively associated Jak2 and Src family 
kinases (SFKs). Binding of leptin to the LepRb induces a conformational change of the 
receptor that leads to transphosphorylation and transactivation of the Jak2 and SFKs 
(Ghilardi et al. 1997). Phosphorylated Jak2 and SFKs in turn phosphorylate critical 
tyrosine residues of LepRb namely Tyr985, Tyr1077 and Tyr1138 that mediates 
downstream signaling events. Phosphorylated Tyr1138 acts as a docking site for 
STAT3, which is phosphorylated by Jak2 (Baumann et al. 1996; Banks et al. 2000). 
This allows STAT3 to dimerize and translocate to the nucleus where it is involved in 
the transcription of a variety of genes, including suppressor of cytokine signaling 
(SOCS) 3. Leptin-mediated signaling through Tyr1077 is implicated in downstream 
signals originating from STAT5 (Gong et al. 2007). Tyr985 undergoes phosphorylation 
by Jak2, which allows for binding and activation of the tyrosine phosphatase SHP2. 
Phosphorylated Tyr985 does not only mediate SHP2/Grb2/ERK signaling, but also 
facilitates SOCS3-mediated feedback inhibition of LepRb signaling (Bjorbaek et al. 
2000)  These signaling pathways emerging from LepRb regulate multiple physiological 
functions that are important for energy homeostasis (Fig 3). 
 
1.2.4.3 Physiological functions mediated by leptin receptor signaling 
Besides long-term energy storage and regulation of food intake, leptin receptor 
signaling is involved in many physiological functions. Lack of functional leptin action 
in ob/ob mice results in sterility, whereas repeated leptin administration rescues 
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reproductive function (Chehab et al. 1996). Leptin signaling through melanocortin 
receptors regulate thyroid hormonal levels, which plays a role in setting the basal 
metabolic rate (Kim et al. 2000). In addition, the pleiotropic actions of leptin are also 
involved in the regulation of growth, bone remodeling, thermogenesis and immunity 
(Lord et al. 1998; Elefteriou et al. 2005; Rahmouni et al. 2009). Furthermore, the 
hormone plays an important role in the regulation of energy metabolism by mediating 
glucose and lipid metabolism. Thus multiple physiological functions are regulated by 
leptin receptor signaling. 
 
1.2.5 Regulation of glucose homeostasis by leptin 
The physiological role of functional leptin action in the regulation of glucose 
metabolism is highlighted from studies on ob/ob and db/db mice. The hormone exerts 
multiple effects on glucose homeostasis. The CNS is the main target for leptin action. 
Intracerebroventricular leptin infusion suppresses hepatic glucose production and 
stimulates peripheral glucose uptake (Kamohara et al. 1997; Liu et al. 1998). In 
addition to central action of leptin on glucose metabolism, in vitro studies provide 
evidence for a direct effect of leptin on glucose metabolism in isolated skeletal muscle 
and hepatocyte (Harris 1998; Aiston et al. 1999). Furthermore, leptin acutely inhibits 
insulin secretion from the β-cells (Khan et al. 2001). In contrast, chronic leptin 
treatment enhances glucose-induced insulin secretion (Khan et al. 2001). These studies 
point to the importance of leptin signaling in the regulation of glucose homeostasis, but 
the critical nodes on the leptin receptor mediating these actions are poorly understood. 
Evidence from studies of mice with disrupted LepRb-STAT3 signaling suggests that 
LepRb-STAT3 independent signals regulate glucose homeostasis (Bates et al. 2005). 
Leptin induces phosphorylation on LepRb at several tyrosine residues and among them 
Tyr985 has been implicated in leptin resistance and attenuation of LepRb signaling 
(Bjorbaek et al. 2000). Fed and fasted leptin and insulin levels are reduced in mice 
expressing a mutant form of LepRb-Tyr985 (Björnholm et al. 2007), which indicates 
that Tyr985 might play a role in the regulation of whole-body glucose metabolism.  
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Figure 3: Leptin receptor signaling. Leptin binding to LepRb initiates a signaling cascade 
that leads to various leptin-mediated physiological functions. The central action of leptin is 
involved in long-term regulation of food intake and energy expenditure. Leptin also suppresses 
hepatic glucose production, stimulates peripheral glucose uptake and lipid oxidation by direct 
and indirect mechanisms. Leptin regulates adiposity by increasing lipolysis and lipid oxidation 
which are mediated by central and peripheral mechanisms. 
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1.3 MITOCHONDRIA AND METABOLIC DISORDERS 
1.3.1 Mitochondrial structure 
Mitochondria are DNA containing organelles that serve as the power house of the cell. 
Mitochondria generate ATP from different sources (glucose, fatty acids and amino 
acids), which fuel the citric acid cycle. The shape, size and number of mitochondria 
within a cell vary and are influenced by the type of tissue (Fernandez-Vizarra et al. 
2011). Oxidative tissues like soleus muscle have more mitochondria compared to 
glycolytic muscle like extensor digitorum longus (EDL). Cardiac myocytes contain 
mitochondria that are larger in size and fewer in number compared to other tissues 
(Veltri et al. 1990). These mitochondrial adaptations are compatible with the different 
metabolic demands imposed on the tissue. Besides ATP and substrate production via 
the citric acid cycle, mitochondria have other functions including regulation of 
apoptosis, Ca
2+
 signaling and reactive oxygen species generation. These organelles are 
capable of morphological changes and redistribute within the cell upon demand by a 
process of fission and fusion, resulting in a dynamic network instead of an isolated 
mitochondrion. These functions of the mitochondria, along with the ATP generating 
capacity, emphasize its role in the regulation of energy homeostasis. 
 
1.3.2 Mitochondrial DNA transcription 
The mitochondrial genome (mtDNA) encodes approximately 3% of mitochondrial 
proteins and the remaining is transcriptionally regulated by nuclear DNA. Out of the 90 
proteins of the respiratory chain complexes, 13 are encoded by mitochondrial DNA, 
which implies that the remaining proteins of the complexes are regulated by nuclear 
DNA (Peralta et al. 2012). Nuclear encoded regulatory proteins and transcription 
factors regulate mtDNA transcription and are targeted to the mitochondria by special 
transport proteins for assembly. Among the various transcription factors, mitochondrial 
transcription factor A (Tfam), the first described mitochondrial transcription factor, 
regulates mtDNA by binding and changing the structure of mtDNA by unwinding the 
promoter region (Fisher et al. 1988; Fisher et al. 1992). In response to cellular energy 
demand, peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-
1α) or PGC-1β are activated and contribute to a coordinated expression of specific 
genes that regulate mitochondrial biogenesis (Bergeron et al. 2001; Amat et al. 2009). 
Lipid oxidation and membrane uncoupling are regulated at the gene level by the 
peroxisome proliferator-activated receptor (PPAR) family of transcription factors. The 
mitochondrial transcription termination factor 3 (MTERF3) is a negative regulator of 
mitochondrial transcription that interacts with the promoter region and suppresses 
transcription initiation (Linder et al. 2005; Park et al. 2007). Silent mating type 
information regulation 2 homolog 1 (SIRT1) has been implicated in the direct 
regulation of mitochondrial biogenesis (Aquilano et al. 2010). Thus, mitochondrial 
biogenesis and activity are integrated to meet cellular energy demands and are 
transcriptionally regulated by nuclear and mitochondrial encoded genome products. 
 
1.3.3  Mitochondrial respiration 
Energy production within the mitochondria is driven through the electron transport 
chain and is coupled to oxidative phosphorylation (OXPHOS). Complex I to complex 
V comprises the oxidative phosphorylation system and is located inside the inner 
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mitochondrial membrane. Among these complexes, complex II is exclusively encoded 
by mtDNA whereas the remaining complexes are derived from proteins encoded by 
both nuclear DNA and mtDNA (Falkenberg et al. 2007). Ultimate breakdown of 
carbohydrates and fatty acids generate reducing equivalents (NADH and FADH2) 
which will be oxidized in OXPHOS to NAD
+
 and FAD. The oxidation generates 
electrons that are transferred to complex I and complex II and move along to complex 
IV and finally to molecular oxygen yielding water. The electrons flowing through the 
complexes drive proton translocation through the inner mitochondrial membrane, 
thereby generating a proton gradient across the inner mitochondrial membrane (Saraste 
1999). This proton movement is mediated through complex I, III and IV (Saraste 1999) 
whereas complex II only serve as an entry point for electrons (Hagerhall 1997). The 
proton motive force that builds up finally drives the ATP synthase leading to the 
formation of ATP from ADP and inorganic phosphate (Boyer 1997). The synthesis of 
ATP is coupled to the energy requirement and, depending on cellular energy demand, 
oxidative phosphorylation and energy production are tightly regulated. 
 
1.3.4 Mitochondria and metabolic disorders 
1.3.4.1 Mitochondrial regulation of lipid metabolism 
The regulation of lipid metabolism is a complex process in which mitochondria play a 
prominent role. Mitochondrial carnitine palmitoyl transferase (CPT)-1 residing on the 
outer mitochondrial membrane converts the intracellular fatty acyl-CoAs into fatty acyl 
carnitine that is translocated into the inner mitochondrial membrane by carnitine acyl 
carnitine translocase (Cohen et al. 1998). The inner mitochondrial membrane harbors 
CPT2, which converts fatty acyl carnitine back to fatty acyl-CoA and undergoes β-
oxidation generating acetyl-CoA moieties that fuels the citric acid cycle. Mitochondrial 
CPT1 and acetyl-CoA carboxylase (ACC) play a role in the regulation of mitochondrial 
lipid oxidation. ACC regulates malonyl-CoA levels (Wakil et al. 1983). An increase in 
malonyl-CoA leads to inhibition of CPT1 thereby reducing mitochondrial entry of long 
chain fatty acyl-CoA, which in turn leads to fatty acid synthesis and triglyceride 
formation (McGarry et al. 1983; Rasmussen et al. 2002). Given the fact that ectopic 
lipid accumulation has detrimental effects on insulin sensitivity (Morino et al. 2006), 
understanding the defects in β-oxidation might be helpful in correcting this metabolic 
abnormality. 
 
1.3.4.2 Mitochondria and type 2 diabetes 
The primary role of mitochondria in the pathogenesis of insulin resistance and type 2 
diabetes is controversial. Mitochondrial protein abundance and mitochondrial 
respiratory capacity is decreased in skeletal muscle biopsies obtained from type 2 
diabetic patients and obese individuals (Kelley et al. 2002; Patti et al. 2003; Ritov et al. 
2010). Mitochondrial ATP production has also been reported to be reduced in oxidative 
skeletal muscle from insulin resistant subjects. Studies performed using diabetic animal 
models provide evidence for defects in mitochondrial bioenergetics (Rogers et al. 
1986). Other studies in skeletal muscle from type 2 diabetic patients provide evidence 
that mitochondrial performance is unaltered or even improved (De Feyter et al. 2008; 
Nair et al. 2008). Diabetic Goto-Kakizaki rats display enhanced hepatic mitochondrial 
bioenergetics (Ferreira et al. 1999). Glucose homeostasis and insulin sensitivity in 
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skeletal muscle are unaltered in a mouse model of respiratory chain dysfunction 
(Wredenberg et al. 2006). Animal models with impairments in mitochondrial oxidative 
phosphorylation displayed enhanced glucose tolerance and insulin sensitivity 
(Pospisilik et al. 2007). Furthermore, mitochondrial capacity in skeletal muscle is 
enhanced in animal models of obesity induced by high fat diet (Stephenson et al. 2012). 
Studies in db/db mice addressing the perturbations of mitochondrial function in 
different tissues points to tissue-specific adaptability of mitochondria in the facet of 
whole-body metabolic derangements (Holmström et al. 2012). These studies in obese 
db/db and high fat fed mice indicate leptin plays a role in mediating tissue-specific 
adaptation and/or alterations in mitochondrial function. Even though, a wealth of 
information regarding mitochondrial function and metabolic dysregulation exists, the 
exact role of leptin in mediating these effects is incompletely resolved. 
 
1.4 AMP-ACTIVATED PROTEIN KINASE (AMPK) 
The evolutionary conserved serine threonine kinase, initially identified as a 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG)-CoA reductase kinase regulating cholesterol 
metabolism, was later identified as a master regulator of cellular energy metabolism 
(Ingebritsen et al. 1978; Clarke et al. 1990). AMPK, is a heterotrimeric complex 
comprised of an anchoring catalytic α-subunit coded by two different genes (α1 and 
α2), a regulatory β-subunit, encoded by β1 and β2, and a regulatory γ-subunit encoded 
by three different genes (γ1, γ2 and γ3), is highly responsive to stress signals that affect 
cellular energy status, thereby acting as a cellular fuel gauge. The catalytic activity of 
the α-subunit requires both the β- and γ-subunits and the triad can exist in 12 tissue-
specific heterotrimeric combinations (Chen et al. 1999; Mahlapuu et al. 2004). Being 
highly sensitive to intracellular changes in AMP to ATP and ADP to ATP ratio 
(Oakhill et al. 2011), AMPK regulates a plethora of metabolic reactions with the final 
outcome of restoring the energy status of the cell. Stress signals like exercise, hypoxia, 
glucose deprivation and osmotic changes activate AMPK, which in turn shuts down 
energy demanding anabolic processes and simultaneously activates catabolic processes 
that yield energy, thereby restoring the intracellular energy balance (Fig 4). Therefore, 
AMPK regulates cellular energy homeostasis by monitoring and integrating the 
nutritional status of a cell. 
 
1.4.1 Regulation of AMPK and upstream kinases 
AMP activates AMPK by allosteric modulation and inhibits dephosphorylation of 
AMPK by protein phosphatase. This regulation requires an intact cystathione-β- 
synthase (CBS) domain in the γ-subunit (Davies et al. 1995; Sanders et al. 2007). In 
addition to AMP, ADP activates AMPK by binding to the γ-subunit (Oakhill et al. 
2011). Activation of AMPK by AMP requires phosphorylation of the α-subunit on 
Thr172 on the activation loop by upstream kinase LKB1 (liver kinase B) and the extent 
of Thr172 phosphorylation is regulated by AMP levels (Hong et al. 2003; Woods et al. 
2003; Sanders et al. 2007). The Ca
2+
/calmodulin-dependent protein kinase kinase-β 
(CAMKKβ) is another upstream kinase that activates AMPK in response to a rise in 
Ca
2+
 concentration, independent of AMP levels (Hawley et al. 1995; Hawley et al. 
2005; Gormand et al. 2011). AMPK regulates energy homeostasis and the activation 
and inhibition of the enzyme are tightly regulated by AMP/ADP and upstream kinases. 
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1.4.2 AMPK and metabolism 
AMPK has a potential role in regulating multiple metabolic pathways in relation to 
energy homeostasis. AMPK activation in the hypothalamus increases food intake 
(Minokoshi et al. 2004), while peripheral activation increases glucose and lipid 
metabolism (Merrill et al. 1997; Carling 2005). At the same time, activation of AMPK 
in response to cellular energy demand turns off energy consuming anabolic processes 
(Li et al. 2003; Chan et al. 2004). The final outcome of AMPK activation is the 
restoration of the energy balance of the organism. 
 
1.4.2.1 AMPK and glucose metabolism 
Activation of AMPK by exercise, muscle contraction, hypoxia or AMPK activators like 
5-aminoimadazole-4-carboximide-1-β-4-ribofuranoside (AICAR) increases skeletal 
muscle glucose uptake (Mu et al. 2001; Jessen et al. 2003; Yu et al. 2003) via 
translocation of GLUT4 to plasma membrane (Kurth-Kraczek et al. 1999). The major 
fate of glucose entering the cell is either oxidation to meet immediate energy demands 
or storage in the form of glycogen. AMPK regulates the fate of glucose in both 
directions. In vitro studies have provided evidence that AMPK phosphorylates critical 
serine residues on glycogen synthase, which consequently inhibits glycogen synthesis 
and enhances glucose oxidation (Miyamoto et al. 2007). Conversely, chronic AMPK 
activation favors glycogen synthesis (Hunter et al. 2011; Vitzel et al. 2013). Increased 
glucose transport associated with AMPK activation results in glucose-6-phosphate 
accumulation that allosterically activates the glycogen synthase (GS) and overrides the 
inhibition imposed by AMPK (Hunter et al. 2011). These pathways can be potentially 
targeted to increase glucose transport and glycogen synthesis in the context of insulin 
resistance to provide a metabolic benefit for people with type 2 diabetes and obesity. 
 
1.4.2.2 AMPK and lipid metabolism 
Skeletal muscle relies on fatty acids as the major fuel source at rest and during 
sustained exercise. This process is regulated at the level of AMPK. AMPK activation 
inactivates ACC by phosphorylating critical serine residues on both ACCα and ACCβ 
(Kudo et al. 1996; Hutber et al. 1997). This in turn decreases malonyl-CoA levels that 
negatively regulates CPT1, allowing transport of long chain fatty acids into the 
mitochondria for β-oxidation. In addition to exercise, AICAR, leptin and adiponectin 
also activate AMPK and increase lipid oxidation (Hutber et al. 1997; Kaushik et al. 
2001; Minokoshi et al. 2002; Yamauchi et al. 2002). AMPK-induced lipid oxidation 
can decrease the elevated intramuscular triglyceride levels associated with insulin 
resistance and obesity and this may confer an insulin sensitizing action on glucose 
metabolism. 
 
1.4.3 Drugs and mutations that modulates AMPK activity 
Anti-diabetic drugs such as metformin and rosiglitazone and hormones such as leptin 
and adiponectin activate AMPK by distinct mechanisms and have therapeutic benefits 
to ameliorate insulin resistance (Fryer et al. 2002; Minokoshi et al. 2002; Yamauchi et 
al. 2002). In addition, a single naturally occurring point mutation on AMPK (γ3
R225Q
) 
plays a positive role in glucose and lipid metabolism. The mutation initially identified 
in RN
-
 Hampshire pigs was associated with increased glycogen content in skeletal 
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muscle and increased citrate synthase activity, indicative of an increased oxidative 
capacity (Milan et al. 2000). Overexpression of this gain-of-function mutation in 
glycolytic skeletal muscle of mice fed a high-fat diet improves insulin sensitivity, 
increases lipid oxidation and reduces intramuscular triglycerides. In vitro experiments 
in COS7 cells show this mutation increases basal AMPK activity independent of 
changes in the AMP:ATP ratio (Barnes et al. 2004). Furthermore, transgenic mice 
bearing the AMPKγ3
R225Q
 mutation in skeletal muscle have increased mitochondrial 
biogenesis (Garcia-Roves et al. 2008). A similar mutation in the AMPK γ3-subunit 
(R200W) in skeletal muscle of humans showed increased glycogen content and 
reduced intramuscular triglyceride content. Although these studies have highlighted the 
importance of AMPK activation in improving insulin sensitivity, whether expression of 
the activating AMPKγ3
R225Q 
mutation in glycolytic skeletal muscle can ameliorate the 
metabolic disturbances observed in the leptin-deficient ob/ob mice is unknown.  
 
Figure 4: AMPK signaling. Various physiological stimuli, hormones and drugs activate 
AMPK. AMPK regulates cellular energy homeostasis by activating pathways that yield energy 
(catabolism) and turning off energy demanding processes (anabolism). 
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2 AIMS 
Leptin and AMPK play prominent roles in the regulation of energy homeostasis. Leptin 
signaling through the long form of the leptin receptor regulates whole-body energy 
metabolism. Leptin action in the brain regulates energy intake and expenditure. 
Furthermore, leptin suppresses hepatic glucose production and stimulates peripheral 
glucose uptake and fatty acid oxidation and may play a role in mitochondrial function. 
AMPK regulates cellular energy homeostasis and its activation leads to increase in 
glucose uptake and lipid oxidation, which further improves metabolic abnormalities 
associated with obesity and insulin resistance. Therefore, the overall aim of this thesis 
was to study the role of leptin and AMPK in the regulation of whole-body glucose and 
energy homeostasis. 
 
The specific sub-aims of this thesis are to elucidate the role of:  
 
 the leptin receptor Tyr985 in mediating glucose metabolism 
 
 leptin in the regulation of tissue-specific mitochondrial function in a mouse 
model of leptin deficiency 
 
 the AMPKγ3 isoform in ameliorating metabolic disturbances arising from 
deficiencies in leptin signaling 
 
 16 
 
3 EXPERIMENTAL SECTION 
3.1 ANIMALS 
All the animals used in Study I, Study II and Study III were on a C57Bl/6J background, 
had free access to food and water and were kept in a temperature controlled 
environment with 12 hour dark and light cycle. For Study I, male and female mice in 
the age range of three to four months were used. Wild type (+/+) and Lepr
tm2Mgmi/tm2Mgmi
 
(l/l) mice were generated as previously described (Björnholm et al. 2007). The exon at 
18b of leptin receptor gene was homologously replaced in such a way that Tyr985 of 
LepR was replaced to Leu985, thereby encoding LepRb
Leu985
. Heterozygous 
Lepr
Leu985
/+ (l/+) animals were intercrossed to generate +/+, l/+ and homozygous l/l 
littermates. In Study II, ob/ob mice and lean littermates were studied at 14-20 weeks of 
age. In Study III, four genotypes namely WT, AMPKγ3
R225Q
 (γ3
R225Q
), ob/ob-WT 
(ob/ob) and ob/ob-γ3
R225Q
 mice were studied. The generation of γ3
R225Q
 has been 
described (Barnes et al. 2004). Heterozygous ob/+-γ3
R225Q
 mice were generated by 
intercrossing ob/+ mice with γ3
R225Q
 mice. These mice were further intercrossed again 
with ob/+ mice to generate WT, γ3
R225Q
, ob/ob and ob/ob-γ3
R225Q
 mice. 
 
Study Animal model Pathway studied 
Study I Lepr
tm2Mgmi/tm2Mgmi
 (l/l) 
LepRb-Tyr985 regulates the SHP2/ERK 
pathway and SOCS3-mediated feedback 
inhibition. Role of LepRb-Tyr985-
mediated signals for whole-body glucose 
homeostasis. 
Study II ob/ob 
Leptin receptor signaling in the context of 
tissue-specific regulation of mitochondrial 
metabolism. 
Study III 
γ3
R225Q 
ob/ob-γ3
R225Q
 
AMPKγ3-mediated signaling pathways in 
the regulation of glucose homeostasis in 
the absence of a functional leptin action. 
 
All animal experiments were approved by the Regional Animal Ethical Committee, 
Stockholm North, and the mice were treated in accordance with the regulation for 
protection of laboratory animals. 
 
3.2 EXPERIMENTAL TECHNIQUES TO MEASURE GLUCOSE AND 
INSULIN SENSITIVITY 
3.2.1 In vivo measurements 
3.2.1.1 Intraperitoneal glucose tolerance test (IPGTT) 
In Study I, four hour fasted +/+ and l/l mice were used and they were individually 
housed at the time of experiment. An intraperitoneal glucose load of 2 g/kg was given 
after measuring basal glucose values (0 min) and subsequently glucose values were 
measured at 15, 30, 60 and 120 minutes using a glucose meter (One Touch Ultra 
Lifescan, Milpitas, CA, USA). Blood samples were collected from the tail at 0 and 15 
minutes for the determination of insulin levels using an ultrasensitive insulin ELISA kit 
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(Crystal Chem Inc, Downers Grove, IL). In Study III, all the study procedures were 
similar except that the intraperitoneal glucose load was 1 g/kg in order to prevent the 
overshoot in glucose values in ob/ob and ob/ob-γ3
R225Q
 mice. 
 
3.2.1.2 Whole-body glucose turnover rate 
Euglycemic-hyperinsulinemic clamps were performed in four hour fasted conscious 
mice for determining whole-body insulin sensitivity. Five days prior to the experiment, 
mice underwent jugular vein cannulation under isoflurane anesthesia and the catheter 
was exteriorized and placed under the skin on the back of the mouse and secured with 
suture. Caprofen (5 mg/kg) was given as an analgesic on the day of surgery and one 
day after the surgery. Body weight and overall health of the mice were monitored daily. 
Any animal that lost body weight more than 10% of their pre-surgery weight was not 
included in the study. Glucose turnover rate and hepatic glucose production were 
determined as described previously (Chibalin et al. 2008). A constant infusion of [3-
3
H] 
glucose (2.5 µCi bolus and infusion flow rate of 0.09 µCi/min) was used to measure 
glucose turnover rate in the basal state and during euglycemic-hyperinsulinemic 
condition. Basal glucose turnover rate was measured after 60 to 70 minutes of constant 
tracer infusion, which was followed by a bolus of insulin (12.5 mU/kg for female mice 
and 25 mU/kg for male mice). Thereafter, a continuous insulin infusion (1.25 
mU/kg/min for female mice and 2.5 mU/kg/min for male mice) was maintained. 
During the insulin clamp, a variable infusion of glucose (30%) was maintained to 
ensure euglycemia. A steady state clamped condition was achieved by 60 to 70 minutes 
after the start of insulin infusion and glucose turnover rate at the clamped condition was 
measured similar to that of basal condition in deproteinated blood. Hepatic glucose 
production was estimated by subtracting the average glucose infusion rate during the 
clamped condition from that of glucose utilization during the clamp. Blood samples 
were collected at basal and clamped condition to measure insulin levels using an 
ultrasensitive insulin ELISA kit (Crystal Chem Inc, Downers Grove, IL, USA). At the 
end of the experiment, animals were euthanized by an overdose of sodium 
pentobarbital and liver and skeletal muscles were rapidly dissected, frozen in liquid 
nitrogen, and stored at -80°C for subsequent signaling experiments. 
 
3.2.1.3 Tissue-specific glucose uptake 
Animals underwent surgery and recovery as described for the whole-body glucose 
turnover rate clamp studies. Tissue specific glucose uptake clamp was performed as 
described (Chibalin et al. 2008). On the day of experiment, after a four hour fast, 
baseline glucose measurements were obtained. A bolus dose of insulin was given 
through the exteriorized jugular vein catheter followed by a continuous constant rate 
insulin infusion. During this period, a variable rate of glucose (30%) was infused to 
ensure euglycemia and a steady state glucose levels (clamped at the basal level) was 
achieved ~60 to 70 minutes from the start of insulin infusion. A bolus of 2-deoxy-D-[1-
14
C] glucose (3 µCi) was injected and blood glucose was subsequently measured at 3, 
6, 10, 15, 20, 30, 40 and 60 minutes. Blood samples (20 µl) were deproteinized to 
measure glucose specific activity. Mice were euthanized by overdose of sodium 
pentobarbital and tissues (detailed in Study III) were quickly dissected and digested in 1 
N NaOH. An aliquot of each sample was processed in per-chloric acid and ZnSO4-
Ba(OH)2 mixture to measure tissue specific glucose uptake. In Study III, insulin 
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infusion rates were 10 mU/kg/min for lean mice (WT and γ3
R225Q
) and 75 mU/kg/min 
in obese mice (ob/ob and ob/ob γ3
R225Q
). Obese mice were clamped at higher insulin 
levels due to severe insulin resistance associated with this model. 
 
3.2.2 In vitro measurement of insulin sensitivity 
3.2.2.1 Insulin-stimulated glucose transport 
Insulin-stimulated glucose transport was estimated in isolated skeletal muscle from 
male and female +/+ and l/l mice. Mice were fasted for four hours and under avertin 
anesthesia (2,2,2-tribromoethanol 99% and tertiary amyl alcohol (1:1 w/v), 500 mg/kg), 
EDL and soleus muscles were isolated with intact tendons and allowed to recover in a 
Krebs-Henseleit buffer (KHB) supplemented with 0.1% radioimmunoassay grade 
bovine serum albumin (BSA) and 5 mM HEPES. Muscles were then incubated in 
absence (basal) or presence of insulin (0.36 or 60 nM corresponding to a submaximal 
or maximal dose, respectively) in a shaking waterbath at 30ºC under a constant gas 
phase of 95% O2 and 5% CO2. Muscles were subjected to the following experimental 
protocol. 
 
Experimental protocol 
Condition Constituents Stimulus 
Recovery – 30 min 
 
5 mM glucose 
15 mM mannitol 
 
no insulin 
Preincubation – 30 min 
 
5 mM glucose 
15 mM mannitol 
 
basal/submax/max 
insulin 
Rinse – 10 min 
 
20 mM mannitol 
 
basal/submax/max 
insulin 
Hot incubation – 20 min 
 
19 mM mannitol 
1 mM 2-deoxyglucose 
(
3
H) 2-deoxyglucose 
(2.5 mCi/ml) 
(
14
C)-mannitol 
(0.7 mCi/ml) 
 
basal/submax/max 
insulin 
 
At the end of the experiment, muscles were blotted on a pre-wet filter paper, trimmed 
of tendons, and freeze clamped with tongs pre-cooled to liquid nitrogen temperature. 
Muscles were stored in -80°C until further analysis. Glucose transport was estimated by 
measuring the accumulation of intracellular 2-
3
H deoxyglucose-6 phosphate (Hansen et 
al. 1994). 
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3.3 IN VITRO MEASUREMENT OF LIPID OXIDATION 
Isolated EDL muscle was used to measure palmitate oxidation as described previously 
(Chadt et al. 2008). EDL muscles were carefully isolated from anesthetized mice. After 
a 30 minute recovery in KHB buffer containing 0.1% BSA and 5 mM HEPES, muscles 
were transferred to a vial containing KHB buffer with tritium labeled palmitate 
(Palmitic Acid, [9,10-
3
H(N)]) and incubated for 120 minutes. Palmitate oxidation was 
measured by determining the amount of tritium labeled water in the incubation 
medium, which was the byproduct of palmitate oxidation. To separate the non-
metabolized palmitate from the tritium labeled water, 200 µl of the incubation medium 
was mixed with 800 µl of activated charcoal slurry (0.1 g activated charcoal powder in 
1ml 0.02 M Tris-HCl buffer, pH 7.5), shaken for 30 minutes to facilitate adsorption of 
non-metabolized palmitate to charcoal. Samples were subjected to centrifugation at 
12000 g for 15 minutes. An aliquot of the supernatant was used to measure tritium 
labeled water using a liquid scintillation beta counter. 
 
3.4 ANALYTICAL METHODS 
3.4.1 Immunoblot analysis 
Homogenates were prepared by placing ~10 to 15 mg of tissue in Eppendorf Safe Lock 
Tubes™ containing ice cold homogenization buffer (300 to 500 µl per tube). A steel 
bead was added to each tube and samples were loaded onto a tissue lyzer (Qiagen 
TissueLyser II) set at 20 Hz (two times for 60 seconds with a 15 second gap). The tubes 
were subjected to end over end rotation at 4ºC for 60 minutes. Samples were subjected 
to centrifugation at 10000 g for 15 minutes, and the supernatant was collected for 
protein measurements using a Pierce BCA protein assay kit (Nordic Biolabs, Täby, 
Sweden). The homogenization buffer contained the following constituents: NaCl 137 
mM, KCl 2.7 mM, MgCl2 1 mM, Na4P2O7 5 mM, NaF 10 mM, Triton X-100 1%, 
Glycerol 10%, Tris pH 7.8 20 mM, EDTA 1 mM, PMSF 0.2 mM, Na3VO4 0.5 mM, 
Protease inhibitory cocktail 1X (Merck Millipore, Nottingham, UK). Homogenates 
were normalized to an equal protein concentration using Laemmli buffer and 
homogenization buffer and heated at 55°C for 20 minutes. For Study III, tissue 
homogenates were subjected to three freeze/thaw cycles to disrupt mitochondria 
(freezing at -80°C overnight, defrost for 1-2 hours at 4°C, vortex followed by -80°C for 
30 min, defrost and vortex). In Study I and III, proteins were separated by SDS-PAGE, 
and transferred to polyvinylidene difluoride membrane (PVDF; Millipore, Billerica, 
MA, USA) that were pre-activated in methanol and blocked in 7.5% (w/v) nonfat dry 
milk. For Study II, proteins were transferred onto nitrocellulose membranes. 
Membranes were incubated with following primary antibodies overnight at 4ºC for the 
determination of phosphorylation and expression of various proteins: phospho-Akt-
Ser473, phospho-glycogen synthase kinase (GSK)-3-α/β-Ser21/Ser9, Akt, GSK-3-α/β, 
IRS-1, ACC, ACCα
Ser79
, phospho-AMPKα
Thr172
 and AMPKα were from Cell Signaling 
Technology, Danvers, MA, USA. Dynamin like 120 kDa protein (OPA1) and TFAM 
were from Abnova, Taipei, Taiwan. NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 9 (NDUFA9), complex I; Succinate dehydrogenase complex, 
subunit A (SDHA), complex II; ubiquinol-cytochrome c reductase core protein I 
(UQCRC1), complex III; Mitochondrial encoded cytochrome c oxidase I (MTCO1), 
complex IV and ATP5B, ATP synthase were from Invitrogen, Carlsbad, CA, USA. 
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Phospho-ACCβ-Ser219/221; MFN2, GAPDH, DNM1L, PPARα and PEPCK were 
from Santa Cruz Biotechnology, CA, USA. Tubulin and IRS-2 was from Millipore, 
Billerica, MA, USA. 
 
The AMPKγ3 antibody was a kind gift from Prof. Grahame Hardie, University of 
Dundee, Dundee, UK and the GLUT4 antibody was a kind gift from Dr Geoffrey 
Holman, University of Bath, Bath, UK. Membranes were incubated overnight in 
primary antibodies, washed in Tris-buffered saline containing 0.02% Tween 20 
(TBST), further incubated with appropriate secondary antibodies for one hour, and 
finally washed again in TBST. Immunoreactive proteins were visualized by enhanced 
chemiluminescence (GE Healthcare, Little Chalfront, UK) and quantified by GS-800 
calibrated densitometer using Quantity One analytical software.  
 
3.4.2 Determination of triglyceride content 
A frozen piece of tissue (~10 to 15 mg) was cut under liquid nitrogen and placed in 
Eppendorf Safe Lock Tubes™. A steel bead and triglyceride extraction buffer (3:2 
heptane-isopropanol solution containing 1% v/v Tween-20) was added to each tube. 
Homogenization of the tissues in the extraction buffer was achieved as described 
above. The tubes were subjected to centrifugation at 1500 g for 15 minutes at 4ºC for 
phase separation. The upper phase was collected and an aliquot was dried in a glass 
tube under vacuum centrifugation. Samples were then used for the determination of 
triglyceride content using a standard enzymatic colorimetric method that estimates the 
glycerol liberated by the hydrolysis of triglyceride present in the sample. A 
triglycerides/glycerol blanked kit was used along with Precinorm L standard (Roche 
Diagnostics Scandinavia, Sweden). 
 
3.4.3 Determination of glycogen content 
A portion of frozen tissue was cut under liquid nitrogen and placed in tight seal micro 
tubes. To each tube, 500 µl of 1N HCl was added and subjected to heating at 100ºC on 
a heated shaking block for 2 hours. The tubes were subjected to centrifugation at 2000 
g for 10 minutes at 4ºC and an aliquot of the supernatant was used for the determination 
of glycogen content (Passonneau et al. 1967). Briefly, 10 µl of the extract was mixed 
with 2 ml of assay buffer (50 mM Tris buffer (pH 8.1), 300 µmol/l ATP, 2 mM MgCl2, 
0.02% BSA, 40 µmol/l NADP, 1 µg/ml glucose-6-phosphate dehydrogensase and 2 µl 
Hexokinase (HK). HK (50-100 µl) was subjected to centrifugation at 4000 g for 5 min 
and the pellet was resuspended in an equal volume of enzyme diluting buffer (20 mM 
imidazole-HCl, pH 7.1; 0.02% BSA). The above reaction mix was thoroughly mixed 
with a vortex and incubated at room temperature for 30 minutes. Glycogen content was 
estimated using fluorometry (TD-700, Tuner Design, Sunnyvale, CA, USA). When 
liver samples were used, a 1:4 dilution with 1 N HCl was required for the detection in 
the normal standard curve range. 
 
3.5 RNA PURIFICATION AND QUANTITATIVE REAL TIME RT-PCR 
Real time polymerase chain reaction using TaqMan technique was used for the 
determination of mRNA expression in tissue samples. Total RNA was isolated from 
tissues using Trizol reagent (Invitrogen) according to manufactures protocol. Isolated 
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RNA was further treated with deoxyribonuclease using a DNA-free kit (Ambion, 
Huntington, UK). The mRNA concentration and purity was measured 
spectrophotometrically using a Nanodrop 1000 (Thermo Scientific, Wilmington, MA, 
USA). Samples were diluted to equal concentrations with sterile and RNase-free water 
and cDNA was synthesized using a Super-Script First-Strand Synthesis system 
(Invitrogen) for Study I and Super-Script III First-Strand Synthesis (Invitrogen) for 
Study II. The mRNA expression of Pck-1 (Mm00440636_m1), G6pc 
(Mm00839363_m1), Scd-1(Mm00772290_m1) [TaqMan gene assay from Applied 
Biosystems] were calculated using ∆Ct method and glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) (Study I) and β-actin (Study II) were used as reference gene. 
 
3.6 MITOCHONDRIAL RESPIROMETRY 
3.6.1 General methodology 
A high resolution closed two chamber mitochondrial respirometer was used to measure 
mitochondrial function (Oroboros Oxygraph-2k; Oroboros Instruments, Innsbruck, 
Austria). Several tissues were isolated and used for the estimation of mitochondrial 
function in this thesis. In Study I, the right liver lobe was dissected and analyzed. In 
Study II, the EDL muscle, soleus muscle and right liver lobe were dissected and 
analyzed. In Study III, the EDL muscle was dissected and analyzed. 
 
Skeletal muscle samples used in Study II and III were placed in ice cold BIOPS 
relaxing solution (2.8 mM Ca2K2EGTA, 7.2 mM K2EGTA, 5.8 mM ATP, 6.6 mM 
MgCl2, 20 mM taurine, 15 mM sodium phosphocreatine, 20 mM imidazole, 0.5 mM 
dithiothreitol and 50 mM MES, pH 7.1). Muscle samples were freed of fat and tendon 
using a fine forceps under a dissection microscope. Fibers were individually combed to 
maximize surface area. Sarcolemmal permeabilization of muscle membrane was 
achieved by transferring finely combed muscle samples into ice-cold BIOPS, 
supplemented with 0.005% (w/v) saponin. Samples were subjected to gentle shaking on 
ice for 10 minutes. Tissue samples were equilibrated in ice cold MiR05 (0.5 mM 
EGTA, 3 mM MgCl2, 60 mM potassium lactobionate, 20 mM taurine, 10 mM KH2PO4, 
20 mM HEPES, 110 mM sucrose and 0.1% [w/v] bovine serum albumin, pH 7.1) for 
30 minutes before transferring them into mitochondrial respirometry chamber. Muscle 
was blotted on a filter paper for 30 seconds and samples weighing 1 to 2 mg were 
transferred into the chamber and mitochondrial respirometry was determined. Mild 
mechanical permeabilization in amino acid-depleted MiR05 was used for liver samples 
and for mitochondrial respirometry, an equivalent of 1 mg of tissue per chamber was 
used along with MiR05 as respirometry medium.  
 
3.6.2 Respirometry measurements 
The “LEAK” respiration, owing to endogenous uncoupling, was measured in the 
absence of ADP by adding malate (final concentration 2 mM) and pyruvate (10 mM). 
Addition of ADP (5 mM) allowed the quantification of oxidative phosphorylation 
capacity or OXPHOS. Complex I mediated oxidation (C I) was evaluated by addition 
of 20 mM glutamate, followed by 10 mM succinate for the convergent electron flow 
through both complex I and II (C I+II). An exogenous protonophore carbonylcyanide-
4-(trifluoromethoxy)-phenyl-hydrazone (FCCP) (titrated to a final concentration of 0.7 
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µM for liver and 0.3 µM for skeletal muscle) was added to measure maximum flux 
through the electron transfer system (ETS I +II). Rotenone (0.1 µM) and antimycin A 
(2.4 µM) were added in subsequent steps to inhibit electron transport through complex 
I (ETS II) and complex III inhibition (Zero respiration) respectively. Zero oxygen flux, 
which is not directly related to electron transfer system, was deducted from the values 
of each previous steps. Absolute oxygen flux (Jo2, [pmol O2/mg/s]) was expressed 
relative to tissue wet weight per second. The relative contribution of each respiratory 
state to maximum oxygen flux described as flux control ratio (FCR) was expressed as 
ratio over ETS I+II. 
 
3.7 IN VIVO LEPTIN TREATMENT 
In Study II and III, a five day leptin treatment protocol was used to assess the effect of 
the hormone on various parameters. Mice (14 to 20 weeks old) were studied. Mice 
were weight-matched within genotypes and between saline or leptin treatment groups. 
Animals were individually housed and acclimatized for a period of 2 to 3 days, during 
which all the experimental animals were handled and injected with saline prior to the 
start of saline/leptin treatment. Recombinant leptin (Peprotech, Rocky Hill, NJ, USA) 
was reconstituted in sterile saline and administered intraperitoneally (1 mg/kg) once 
daily between 15:00 and 16:00 hrs for a period of five days, during which body weight 
and food intake were recorded. Body composition analysis (fat mass and lean mass) 
was performed using MRI scans (Echo MRI, Houston, TX, USA) before and after 
saline/leptin treatment. On the sixth day morning, mice were anesthetized with avertin 
(2,2,2-tribromoethanol 99% and tertiary amyl alcohol (1:1 w/v), 500 mg/kg) and tissues 
were collected for various experimental protocols. In Study III, mice were fasted for 
four hours prior to tissue collection. 
 
3.8 STATISTICAL ANALYSES 
Data are presented as mean ± SEM. Unpaired student’s t-test, one-way ANOVA or 
two-way ANOVA was used to identify significance between the different groups as 
further detailed in each study. Results that were identified as statistically significant 
using a one-way ANOVA or two-way ANOVA were further evaluated by an 
appropriate post hoc analysis as further detailed in each study. p<0.05 was considered 
to be statistically significant. 
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4 RESULTS AND DISCUSSION 
 
4.1 LEPTIN SIGNALING AND GLUCOSE HOMEOSTASIS 
4.1.1 LepRb-Tyr985 regulates whole-body glucose homeostasis 
Signaling through the long form of the leptin receptor activates the Jak2-mediated 
phosphorylation of Tyr985, Tyr1077 and Tyr1138 of the leptin receptor. Among these 
residues, phosphorylated Tyr985 mediates the SHP2-Grb2-ERK signaling pathway and 
also acts as a docking site for SOCS3 (Banks et al. 2000). Attenuation of leptin 
signaling by ligand activation, as well as mediation of leptin resistance, is facilitated by 
SOCS3 binding to Tyr985 (Bjorbaek et al. 2000), which indicates that this pathway 
mediates leptin sensitivity. The role of LepRb-Tyr985 in mediating glucose 
homeostasis is poorly understood. Study I focuses on the role of LepRb-Tyr985 in 
regulating whole-body glucose homeostasis. 
 
4.1.1.1 Glucose tolerance is improved in LepRb-Tyr985 mutant (l/l) mice 
Initial characterization of l/l mice showed that glucose levels in the fed state were 
normal in male and female mice with reduced insulin levels in female mice (Björnholm 
et al. 2007). Intraperitoneal glucose tolerance revealed improved insulin sensitivity and 
glucose tolerance. Female l/l mice had lower insulin levels under basal conditions and 
in response to a glucose challenge, along with normal glucose tolerance. In contrast, 
male mice showed improved glucose tolerance with normal insulin levels compared to 
that of +/+ mice (Fig 5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: LepRb-Tyr985 mutation confers improved glucose homeostasis. Intraperitoneal 
glucose tolerance tests were performed in 4 hour fasted +/+ (white bars) and l/l (black bars) 
mice. Plasma glucose (mM) and insulin (pM) values during the glucose tolerance test in female 
(F; A and B) and male (M; C and D) +/+ and l/l mice. Results are mean ± SEM. *, p<0.05 vs. 
+/+; †, p<0.01 vs. +/+ mice (n = 9-12). (Tom et al. 2011).  
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Previous studies provide evidence that l/l mice have slightly lower body weight, 
reduced adipose tissue mass, and enhanced leptin sensitivity (Björnholm et al. 2007). 
These moderate alterations in the body composition, combined with increased leptin 
sensitivity, can confer improvements in glucose homeostasis. Experimental approaches 
leading to reduction in adipose tissue mass improve glucose tolerance (Wetter et al. 
1999; Ntambi et al. 2002; Yan et al. 2013). Leptin signaling influences insulin 
sensitivity (Carvalheira et al. 2005). The improved glucose tolerance and insulin 
sensitivity in l/l mice could stem from enhanced hepatic insulin sensitivity and/or an 
enhanced peripheral glucose disposal. To differentiate hepatic versus peripheral insulin 
sensitivity, a euglycemic-hyperinsulinemic clamp in conscious mice was performed.  
 
4.1.1.2 LepRb-Tyr985-mediated signals are important for hepatic and peripheral 
insulin sensitivity 
The euglycemic-hyperinsulinemic clamp is considered as a golden standard to asses 
insulin sensitivity (DeFronzo et al. 1979). This method, when combined with a radio 
isotope technique, allows for the determination of hepatic vs. peripheral glucose fluxes 
during the clamp (DeFronzo et al. 1979). Female mice were clamped at an insulin 
infusion rate of 1.25 mU/kg/min, whereas male mice were clamped at 2.5 mU/kg/min 
insulin. The glucose turnover rate in the basal state, which is indicative of endogenous 
glucose production, was similar between female and male +/+ and l/l mice (Fig 6 A and 
C). The above results are in agreement with the glucose tolerance results, which show 
basal glucose values were similar between +/+ and l/l mice. In female mice, insulin-
stimulated peripheral glucose utilization was similar between +/+ and l/l mice and 
increased ~1.8 fold over basal values (Fig 6 A and C). During the clamped condition, 
hepatic glucose production was completely suppressed in female l/l mice (p<0.001 vs. 
+/+) in response to insulin, whereas this suppression was only 46% in the +/+ mice. 
This indicates that LepRb-Tyr985 influences hepatic insulin sensitivity (Fig 5 B). The 
LepRb-Tyr985 mutation in the male mice not only improved suppression of hepatic 
glucose production (p<0.05 vs. +/+), but it also enhanced peripheral glucose utilization 
during the clamp (p<0.01 vs. +/+) (Fig 6 C and D). 
 
Female l/l mice displayed enhanced hepatic insulin sensitivity, whereas the male l/l 
displayed both hepatic and peripheral insulin sensitivity. This difference in insulin 
sensitivity between males and females could be partly attributed to the influence of 
testosterone levels (Sato et al. 2008). Castration of male l/l mice significantly reduces 
fat pad mass, whereas testosterone treatment restored fat mass to levels in wild-type 
mice (Johnson et al. 2012).Experiments evaluating glucose tolerance in castrated l/l 
mice may be performed in the future to directly address the influence of the sex on 
peripheral insulin sensitivity. 
 
Body weight is one factor that can influence insulin sensitivity. Body weight of female 
and male l/l mice was significantly lower than the corresponding +/+ mice (Study I, 
Table 1). Clamp data was analyzed in a subset of body weight-matched +/+ and l/l mice 
to exclude the possibility that enhanced insulin sensitivity in l/l mice is due to reduced 
body weight or adiposity. Hepatic insulin sensitivity was increased in body weight-
matched female l/l mice as evidenced by an enhancement in the suppressive effect of 
insulin on of hepatic glucose production (p<0.05 vs. +/+). Glucose utilization during 
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the basal, as well as insulin-stimulated conditions was similar in +/+ and l/l mice (body 
weight: +/+, 19.7 ± 0.8 g vs. l/l, 19.3 ± 0.5 g). Male +/+ and l/l mice matched body 
weight (body weight: +/+, 28.0 ± 0.2 g vs. l/l, 27.3 ± 0.3 g) had similar rates of basal 
glucose utilization. Insulin-stimulated glucose utilization and suppression of hepatic 
glucose production tended to be enhanced in male l/l mice, but this difference was not 
statistically significant compared to +/+ mice. These results highlight a primary role for 
LepRb-Tyr985 in mediating insulin sensitivity. Moreover, they point to only a 
secondary role for reduced body weight. 
 
 
Figure 6: LepRb-Tyr985 mutation enhances whole-body insulin sensitivity. Basal and 
insulin-stimulated peripheral glucose utilization (Rd) and hepatic glucose production (Ra) 
during a euglycemic-hyperinsulinemic clamp in 4-hour fasted +/+ (white bars) and l/l (black 
bars) mice. Glucose utilization and insulin-mediated suppression of hepatic glucose production 
are presented for female (A and B) and male (C and D) +/+ and l/l mice. n=7-9. Results are 
mean±SEM, *p<0.05, †p<0.01 and #p<0.001 versus +/+ mice. (Tom et al. 2011). 
 
4.1.2 LepRb-Tyr985 mediates hepatic insulin sensitivity 
Leptin signaling interacts with canonical insulin signaling cascades by central and 
peripheral mechanisms (Liu et al. 1998; Carvalheira et al. 2003). In the present study, 
canonical insulin signaling pathways involved in the regulation of hepatic insulin 
sensitivity were assessed. Liver was frozen at the end of a 75 minute insulin infusion 
and phosphorylation and abundance of insulin signaling proteins (tyrosine 
phosphorylation of the insulin receptor, IRS-1 and IRS-2 and phosphorylation of Akt-
Ser473) was evaluated by Western blot. Interestingly, insulin signaling was similar 
between +/+ and l/l mice. During the clamp experiment, l/l mice responded to the 
insulin infusion very rapidly and blood glucose dropped faster compared to the +/+ 
mice. This prompted an evaluation of hepatic insulin signaling cascades after a 10 
minute insulin infusion. Tyrosine phosphorylation of the insulin receptor, IRS-1 and 
IRS-2 and phosphorylation of Akt-Ser473 was similar between +/+ and l/l mice. We 
also determined whether alterations in gluconeogenic genes could account for the 
enhanced hepatic insulin sensitivity in l/l mice. Hepatic gene expression of PEPCK and 
G6Pc were unaltered between +/+ and l/l mice. These results provide evidence to 
suggest that increased hepatic insulin sensitivity conferred by LepRb-Tyr985 may not 
be a direct consequence of enhanced LepRb signaling in the liver. 
 
The role of hypothalamus in the regulation of hepatic glucose production is well 
established (Obici et al. 2002; Pocai et al. 2005). Acute intracerebroventricular 
administration of leptin or insulin regulates hepatic glucose production (Liu et al. 1998; 
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Obici et al. 2002). The precise mechanism by which the LepRb-Tyr985 mutation 
influences hepatic insulin sensitivity is unclear. An enhanced hypothalamic leptin 
signaling may possibly play a role in mediating hepatic insulin sensitivity in l/l mice. 
pSTAT3 is enhanced in hypothalamic arcuate nucleus of l/l mice in the presence of low 
leptin levels as compared to +/+ mice, indicative of enhanced leptin signaling in the 
hypothalamus (Björnholm et al. 2007). Given that leptin signaling influences insulin 
sensitivity (German et al. 2009) and central insulin signaling regulates hepatic glucose 
production (Liu et al. 1998), any enhancement in leptin signaling in the hypothalamus 
might amplify the central insulin mediated inhibition of hepatic glucose production. 
SOCS3 is another molecule that is connected to leptin sensitivity. SOCS3 is a negative 
regulator of leptin signaling and is implicated in leptin resistance (Bjorbaek et al. 2000). 
SOCS3 haploinsufficient mice showed enhanced leptin sensitivity and improved 
glucose homeostasis (Howard et al. 2004; Kievit et al. 2006). Moreover, 
overexpression of SOCS3 in hypothalamus leads to leptin resistance, obesity and 
disturbances in glucose homeostasis (Reed et al. 2010). SOCS3 has also been 
implicated in mediating insulin resistance (Rui et al. 2002). In l/l mice, SOCS3-
mediated feedback inhibition of leptin signaling was blunted since phosphorylated Tyr-
985 of the leptin receptor is needed for this feedback loop to function (Bjorbaek et al. 
2000). This suggests that a lack of SOCS3 signaling in l/l mice could enhance hepatic 
insulin sensitivity by central mechanisms. Furthermore, AgRP levels in the 
hypothalamus are reduced in l/l mice (Björnholm et al. 2007). Given that insulin-
mediated suppression of AgRP levels in the AgRP neurons plays a role in the 
regulation of suppression of hepatic glucose production (Konner et al. 2007; Lin et al. 
2010), reduced AgRP levels in the l/l mice might potentiate insulin ability to suppress 
hepatic glucose production. These results suggest that enhanced central leptin signaling 
might enhance hepatic insulin sensitivity in l/l mice. 
 
4.1.3 Limitations of Study I 
We have not been able to differentiate as to whether the LepRb-Tyr985-mediated 
changes in glucose metabolism are due to primary effects brought about by central 
regulation or secondary effects via adaptive responses in peripheral tissues. Another 
limitation is that the present study cannot determine whether the enhanced suppression 
of hepatic glucose production is due to decreased glycogenolysis and/or decreased 
gluconeogenesis during the euglycemic-hyperinsulinemic clamp. Thus further studies 
are required to identify the molecular signaling mechanisms connecting the 
enhancement in hepatic insulin sensitivity with the insulin signaling cascade. 
 
4.2 MITOCHONDRIAL FUNCTION IN OB/OB MICE: ROLE OF LEPTIN 
The ob/ob mice are hyperphagic, hyperglycemic, obese and exhibit perturbations in 
whole-body energy metabolism owing to the lack of the hormone leptin. Leptin 
supplementation to ob/ob mice improves insulin sensitivity and other complications 
associated with obesity (Halaas et al. 1995). Mitochondrial function has a major role in 
regulating whole-body metabolism. The role of mitochondrial dysfunction in the 
development of insulin resistance and type 2 diabetes is well documented (Patti et al. 
2003; Petersen et al. 2004; Lowell et al. 2005), but nevertheless some controversy 
exists. Tissue-specific differences in mitochondrial properties such as mitochondrial 
mass, cytochrome c oxidase activity, mitochondrial DNA copy number are adapted to 
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integrate varying metabolic demands unique to each specific tissue (Weibel et al. 1969; 
Eisenberg et al. 1975; Eisenberg et al. 1976; Gagnon et al. 1991; Wiesner et al. 1992). 
Tissue-specific differences in mitochondrial function might be altered in the context of 
obesity and type 2 diabetes (Brady et al. 1985; Ferreira et al. 2003; Hancock et al. 2008; 
Raffaella et al. 2008; Holmström et al. 2012). Study II was designed to address the role 
of leptin in modulating tissue-specific mitochondrial function in the setting of obesity 
and associated insulin resistance. 
 
4.2.1 Mitochondrial respiration in glycolytic skeletal muscle 
Glycolytic skeletal muscle adapts to obesity in ob/ob mice through increases in 
mitochondrial respiration. Maximum electron transfer capacity measured at ETS I +II 
was increased in EDL muscle (p<0.05) compared to lean littermates, along with a trend 
for enhanced electron transport capacity at ETS II (p=0.069) (Fig 7 A). These 
mitochondrial adaptations in glycolytic skeletal muscle were also observed in obese 
diabetic db/db mouse (Holmström et al. 2012). Consistent with the functional data, 
protein abundance of the SDHA subunit of complex II (p<0.01), MTCO1 subunit of 
complex IV (p<0.05) and ATP5B subunit of complex V (p<0.05) are increased (Fig 7 
C-E). The reason for these adaptations can be multifactorial. EDL muscle from ob/ob 
mice has fiber type differences, with increased type II A fibers having larger surface 
area and proportionately lower type II B fibers (Warmington et al. 2000). The fiber type 
alteration, coupled with increased lipid availability and elevated circulating free fatty 
acids, increases mitochondrial biogenesis in glycolytic skeletal muscle (Garcia-Roves 
et al. 2007). This metabolic milieu might lead to an increase in mitochondrial 
respiration in EDL muscle from ob/ob mice. We also confirmed our findings in Study 
III, where an increase in mitochondrial respiration was seen in glycolytic EDL muscle 
from ob/ob mice. Collectively, these studies provide evidence that glycolytic skeletal 
muscle can adapt to increase mitochondrial respiration in the context of obesity. 
 
With an increase in mitochondrial respiration in EDL muscle from ob/ob mice, an 
increase in markers of mitochondrial biogenesis and stability was expected. However, 
TFAM protein abundance was significantly lower in ob/ob mice, the OPA1 ratio of the 
short to long form was increased along with increased DNM1L protein level. These 
points suggest that mitochondria are undergoing fission or fragmentation, since MFN2, 
which is responsible for fusion, is unaltered. The results of the present study are 
compatible with the previous finding of increased mitochondrial fission or 
fragmentation in EDL muscle from db/db mice. The long-term or age-dependent 
consequences of this “obesity-associated” mitochondrial profile might decrease 
mitochondrial respiration over time. 
 
Analysis of flux control ratio in EDL muscle provided evidence for reduced C I and CI 
+ II contribution in ob/ob mice compared to lean mice. Since the protein constituents 
that comprise the complexes of the respiratory chain were unaltered (C II, C IV and C V 
were increased), the decrease in FCR could indicate mitochondrial inefficiency. This 
might have arisen from the relatively increased ETS I + II value that is used for 
normalizing oxygen flux.   
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Figure 7: Mitochondrial respiration in EDL muscle from ob/ob mice. (A) Oxidative 
phosphorylation and electron transport system, n=4-9. (B) Flux control ratio highlighting the 
relative contribution of each given respiratory state to ETS I +II, n=4-9. (C-E) Protein markers 
of ETS complexes II, IV and V; (F-H) protein markers of mitochondrial biogenesis and 
dynamics, n=6-8. Results are mean ± SEM. Open bar - saline-treated; closed bar - leptin-
treated. *p<0.05, †p<0.01, ‡p<0.001 vs. lean (+/?) saline-treated mice. §p<0.05 vs. ob/ob 
saline-treated mice. 
 
Mitochondrial respiration in glycolytic EDL muscle was unaltered after five days of 
leptin treatment. Leptin stimulates lipid oxidation in under in vivo and in vitro 
conditions through activation of AMPK (Muoio et al. 1997; Minokoshi et al. 2002). 
Activation of AMPK is associated to mitochondrial biogenesis (Garcia-Roves et al. 
2008). In the present study, leptin action through AMPK was expected to increase 
mitochondrial biogenesis and mitochondrial respiration. Initial studies addressing the 
effect of leptin on lipid oxidation indicate that the EDL muscle is unresponsive to leptin 
(Minokoshi et al. 2002). The effect of leptin on mitochondrial biogenesis is mediated 
by multiple mechanisms. Leptin treatment increases PGC-1α expression and induces 
endothelial nitric oxide synthase, highlighting a role in mitochondrial biogenesis. 
Concomitantly, proinflammatory cytokines like TNF-α negatively regulate 
mitochondrial biogenesis. Indeed, TNF-α levels are markedly higher in ob/ob mice. 
Future studies testing higher doses of leptin or more frequent administration may 
enhance mitochondrial biogenesis. 
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4.2.2 Mitochondrial respiration in soleus muscle from ob/ob mice is 
unaltered 
Mitochondrial respiration in soleus muscle was similar between lean and ob/ob mice. 
Moreover, leptin treatment did not alter the respiratory state or the flux control ratios 
(Fig 8 A). Protein abundance of several markers of the respiratory chain complex was 
unaltered between saline- and leptin-treated lean and ob/ob mice. Saline-treated lean 
mice had higher TFAM protein abundance compared with saline- and leptin-treated 
ob/ob mice (p<0.001), whereas leptin treatment reduced TFAM levels in lean mice 
(p<0.01) (Fig 8 B). The mitochondrial fusion-mediating protein MFN2 tended to 
increase with leptin treatment (Fig 8 C). Oxidative tissues, such as the soleus muscle, 
display defective glucose and abnormal lipid metabolism in the context of obesity and 
type 2 diabetes (Cuendet et al. 1976). Obesity arising from a high fat diet increases 
mitochondrial mass and hence respiratory capacity in rat soleus muscle (Stephenson et 
al. 2012). Thus, mitochondrial adaptations might be occurring as a consequence of 
metabolic perturbations associated with obesity and type 2 diabetes. However, these 
adaptations are insufficient to correct the metabolic defects in glucose and lipid 
metabolism in oxidative tissues in the obese mice. Conversely, mitochondrial 
respiration is decreased in soleus muscle from diabetic and obese db/db mice 
(Holmström et al. 2012). The difference in mitochondrial respiration in soleus muscle 
from db/db and ob/ob mice may be attributed to strain differences. The data reported 
from soleus muscle in ob/ob mice indicates that metabolic disturbances in glucose and 
lipid metabolism in oxidative skeletal muscle are dissociated from mitochondrial 
function. Furthermore, short-term leptin treatment does not alter the mitochondrial 
respiratory capacity. 
 
Figure 8: Mitochondrial respiration and protein markers of mitochondrial biogenesis and 
dynamics in soleus skeletal muscle from ob/ob mice. (A) Oxidative phosphorylation and 
electron transport system (ETS), (B, C) TFAM and MFN2 protein levels. Open bar - saline-
treated; closed bar - leptin-treated. Results are mean ± SEM. (n=6-8). †p<0.01, ‡p<0.001 vs. 
lean (+/?) saline-treated mice.  
 
Previous studies in ob/ob mice provide evidence to suggest that leptin treatment alters 
fiber type composition in oxidative muscle, with a net increase in type II B fibers and a 
concomitant decrease in type II A fibers (Warmington et al. 2000). This shift to a 
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greater proportion of fast twitch glycolytic fibers may mitigate any effect of slight 
increase in mitochondrial biogenesis markers after leptin treatment. The similarities in 
mitochondrial respiration between lean +/? and ob/ob saline-treated mice suggest that 
obesity, due to a lack of functional leptin action, does not affect mitochondrial 
respiration in oxidative skeletal muscle. The effect of leptin on lipid oxidation is 
biphasic involving a direct activation of AMPK by shifting ADP to ATP ratio and 
indirect activation via the sympathetic nervous system. Experimentally, these effects of 
leptin on lipid oxidation are diminished after six hours (Minokoshi et al. 2002). Thus, 
the peak effect of leptin on mitochondrial respiration may have been missed, since 
tissues were isolated 16 hours after the last leptin injection. 
 
4.2.3 Hepatic mitochondrial respiration is impaired in ob/ob mice 
The liver influences energy metabolism by regulating glucose fluxes under fed and 
fasting conditions. In addition, the liver also plays an integral role in lipid metabolism. 
Ectopic lipid accumulation in hepatic tissues leads to insulin resistance. Moreover, an 
increase in hepatic glucose production is a characteristic feature of obese insulin 
resistant or type 2 diabetic patients, animal models of obesity and diabetes. The role of 
mitochondria in regulating hepatic energy metabolism is incompletely resolved. Leptin 
receptor deficient db/db mice are hyperglycemic, exhibit hepatic triglyceride 
accumulation and have decreased hepatic mitochondrial respiration (Holmström et al. 
2012). Treating ob/ob mice with leptin and studying hepatic mitochondrial respiration 
will highlight the role of leptin in regulating hepatic oxidative capacity. 
 
Mitochondrial respiratory capacity at ETS I + II and ETS II were reduced in saline-
treated ob/ob mice compared to saline-treated lean (+/?) mice (p<0.01 and p<0.001 
respectively). A similar trend in C I+II was also observed in saline-treated ob/ob mice 
(p=0.062). In the present study, leptin treatment did not alter mitochondrial respiration 
in liver (Fig 9 A). Flux control ratio for OXPHOS and C I+II was increased in saline-
treated ob/ob mice (p<0.001; p<0.05 vs. saline-treated lean (+/?) mice respectively (Fig 
9 B). Leptin treatment increased Leak and OXPHOS respiration in lean mice (p<0.05 
vs. saline-treated lean mice). Protein levels of SDHA, which is the catalytic subunit of 
C II, was decreased in ob/ob mice and was unaltered by leptin treatment (p<0.05 vs. 
saline-treated lean (+/?) mice (Fig 9 D). Abundance of the C I subunit protein, 
NDUFA9, tend to be increased in saline treated ob/ob mice (p=0.058) (Fig 9 C). TFAM 
levels were decreased in saline-treated ob/ob mice (p<0.05 vs. saline-treated lean mice) 
and increased by leptin treatment (p<0.05 vs. ob/ob saline-treated mice), (Fig 9 E). The 
increased OPA1 ratio (short to long isoform) in saline-treated ob/ob mice was reduced 
by leptin treatment (p<0.05 vs. saline-treated ob/ob mice) (Fig 9 F). PPARα levels were 
lower in ob/ob mice (p<0.001 vs. saline-treated lean mice) (Fig 9 G). With respect to 
the hepatic mitochondrial respiratory capacity, the results from the present study are 
compatible with previous results (Garcia-Ruiz et al. 2007; Perfield et al. 2013). Thus, 
the reduction in hepatic mitochondrial oxidative capacity in ob/ob mice could be due to 
multiple defects in respiration. Furthermore, short-term leptin treatment failed to fully 
restore hepatic mitochondrial oxidative capacity. 
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Figure 9: Hepatic mitochondrial respiration is reduced in ob/ob mice. (A) Oxidative 
phosphorylation and electron transport system (n=5-9). (B) Flux control ratios (n=4-9). (C-D) 
Protein markers of complex I and II. (E) TFAM protein levels, (F) OPA1 ratio. (G) PPARα 
protein abundance, (n=6-8, for immunoblot analysis). Results are mean ± SEM. *p<0.05, 
†p<0.01, ‡p<0.001 vs. lean (+/?), saline-treated mice. §p<0.05 vs. ob/ob saline-treated mice. 
 
Results from mitochondrial respiration in ob/ob mice suggest that the primary defect in 
the electron transport capacity lies at the level of C II. The reduction in electron transfer 
at the level of C II could be attributed to the relatively low abundance of the catalytic 
subunit of C II, SDHA. Succinate dehydrogenase connects the citric acid cycle to the 
electron transport chain and catalyzes the oxidation of succinate to fumarate. The C II 
activity is decreased in patients with non-alcoholic hepatic steatosis (Perez-Carreras et 
al. 2003). The present data in ob/ob mice is compatible with previous results (Perez-
Carreras et al. 2003) showing a massive accumulation of intrahepatic triglyceride 
content (Study II, Fig 1E) in obesity. In the present study, leptin treatment decreased 
liver weight and intrahepatic triglyceride content, but mitochondrial respiration was 
unaffected. Leptin-mediated depletion of hepatic triglyceride content is independent of 
mitochondrial respiration (β-oxidation) and is mediated by increased hepatic lipid 
export (Singh et al. 2009). Conversely, leptin treatment represses the elevated stearoyl-
CoA desaturase-1 (SCD1) activity in the liver from ob/ob mice and is thought to 
enhance β-oxidation with concomitant triglyceride depletion (Cohen et al. 2002). Other 
studies have provided evidence that hepatic mitochondrial respiration is enhanced in 
ob/ob mice (Brady et al. 1985; Singh et al. 2009). The discrepancy between previous 
studies and the present results could stem from different reasons. One major difference 
is the experimental methodology used between studies. Previous studies were 
performed in isolated mitochondrial fractions, whereas the present results were 
obtained using mechanically permeabilized liver tissues. Isolation techniques might 
unknowingly lead to a bias in mitochondrial selection. Mitochondria in most 
pathological states have altered volume and density. Differential centrifugation, which 
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is essential for mitochondrial isolation procedures, may lead to a selection of a specific 
pool of mitochondria that might yield very different results. Mitochondria usually exist 
as a network of structures and isolation procedures disrupts this network, which might 
influence the final experimental readout (Kuznetsov et al. 2008). Decreased TFAM 
protein abundance along with increased OPA1 (short to long form) protein abundance 
in the saline-treated ob/ob mice indicates increased mitochondrial stress. Even though, 
leptin treatment did not increase mitochondrial respiration, improved mtDNA stability 
and decreased mitochondrial stress, as evidenced by increased levels of TFAM and 
reduced OPA1 levels, was observed. 
 
4.2.4 Effect of leptin treatment on whole-body energy metabolism 
Leptin treatment decreased food intake and concomitantly reduced body weight in both 
ob/ob mice and lean mice. Moreover, the amplitude of these effects was more 
pronounced in obese mice. In Study II, lean and fat mass were decreased by leptin 
treatment, whereas in Study III, the effect of leptin treatment was more pronounced on 
fat mass. The effect of leptin on food intake is well-established and is under central 
control (Zhang et al. 1994; Halaas et al. 1995; Pelleymounter et al. 1995). Leptin 
reduces fat mass by direct and indirect mechanisms, even at doses that do not reduce 
food intake (Levin et al. 1996). These effects of leptin on food intake and body 
composition are consistent with the physiological role of leptin in energy homeostasis. 
 
Leptin treatment partially corrected the hepatic steatosis in ob/ob mice (Study II). Liver 
weight was higher in saline-treated ob/ob mice (p<0.001 vs. lean, saline-treated mice). 
Leptin treatment for five days reduced liver weight in ob/ob mice (p<0.001 vs. ob/ob, 
saline treated mice) and lowered the hepatic triglyceride level (p<0.01 vs. ob/ob saline-
treated mice). These effects of leptin in the absence of any increase in mitochondrial 
respiration suggest that the reduction in hepatic triglyceride content might have resulted 
from an increase in hepatic lipid export (Singh et al. 2009) or a decrease in triglyceride 
synthesis. Acute infusion studies have provided evidence that leptin-mediated hepatic 
triglyceride depletion is a result of increased hepatic β-oxidation, with no change in 
lipid export. This increase in β-oxidation was associated with increased ACC 
phosphorylation (Huang et al. 2006). In the present study, both lipid export and 
increased β-oxidation might have occurred. We cannot exclude the possibility that an 
increase in β-oxidation may have occurred, since the mitochondrial respiration in 
isolated liver was performed approximately 16 hours after the last leptin injection. 
Leptin also has direct inhibitory effect on insulin secretion, which might indirectly 
decrease triglyceride synthesis (Milstein et al. 1956; Emilsson et al. 1997; Kieffer et al. 
1997). 
 
The intramuscular triglyceride content was reduced in leptin-treated ob/ob mice (Study 
II, Fig 1 E and Study III, Fig 6 B). Leptin treatment also depletes intramuscular 
triglyceride content (Shimabukuro et al. 1997) by stimulating lipid oxidation by central 
and peripheral mechanisms (Minokoshi et al. 2002). Leptin also opposes the lipogenic 
effect of insulin on lipid partitioning and favors lipid oxidation (Muoio et al. 1999) and 
is regulated by AMPK-mediated inhibition of ACC activity (Minokoshi et al. 2002). 
The inhibitory effect of leptin on insulin secretion and gene expression also normalizes 
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insulin levels in ob/ob mice (Seufert et al. 1999), which when combined with an 
inhibition on ACC activity, leads to triglyceride depletion in skeletal muscle. 
 
Skeletal muscle glycogen content in ob/ob mice was reduced by leptin treatment (Study 
II, Fig 1F and Study III, Fig 6 A). Leptin also inhibits glycogen synthesis under basal, 
as well as insulin-stimulated condition in skeletal muscle (Liu et al. 1997). This effect 
of leptin on glycogen synthesis could partly be mediated by AMPK-induced inhibition 
of GS (Bultot et al. 2012). Even though our results are consistent with this finding, 
others have reported that leptin increases basal and insulin-stimulated glycogen 
synthesis (Harris 1998). Indeed, leptin may regulate skeletal muscle glycogen content 
at multiple levels. For instance, leptin may inhibit insulin secretion and insulin-
mediated gene expression (Seufert et al. 1999). Alternatively, leptin may activate 
AMPK and inhibit GS (Bultot et al. 2012). In addition, the reduction in food intake may 
favor glycogenolysis. Indeed, all of these possibilities may account for the reduced 
glycogen content after leptin treatment.  
 
4.2.5 Limitations of Study II 
Leptin has a potent effect on food intake. Therefore, to exclude the possibility that 
leptin-mediated reduction in food intake may influence the results, a group of pair fed 
animals could have been included. However, one strength of the work was the inclusion 
of lean wild-type (leptin-positive) mice treated with saline or leptin. The use of the 
present mitochondrial respiration protocol (glutamate and succinate) to assess 
respiration may not completely reflect β-oxidation. Therefore a modified protocol using 
palmitoyl-carnitine might give a more precise tool to assess leptin-mediated responses 
on mitochondrial respiration (β-oxidation). The acute effect leptin on β-oxidation was 
not assessed in the present study and therefore future studies to study mitochondrial 
respiration over a time course (i.e. 15 minutes to 6 hours) may address this issue. 
 
4.3 AMPK ACTIVATION IN THE CONTEXT OF INSULIN RESISTANCE 
ASSOCIATED WITH LEPTIN DEFICIENCY 
 
4.3.1 AMPK activation and insulin sensitivity 
AMPK is comprised of a heterotrimeric complex with α, β and γ subunits that act 
collectively as a metabolic sensor to regulate energy metabolism (Davies et al. 1994; 
Hardie et al. 1997). AMPK is highly sensitive to changes in intracellular AMP/ATP 
and ADP/ATP ratio in response to cellular stress (Corton et al. 1994; Oakhill et al. 
2011), AMPK activation restores cellular energy status by stimulating glucose uptake 
and lipid oxidation (Merrill et al. 1997; Bergeron et al. 1999; Hayashi et al. 2000; 
Kaushik et al. 2001). This effect of AMPK on glucose uptake is insulin-independent 
(Hayashi et al. 2000). Physiological or experimental approaches that activate AMPK 
have been shown to ameliorate insulin resistance and improve energy metabolism in 
type 2 diabetes and obesity (Musi et al. 2001; Halseth et al. 2002; Song et al. 2002). A 
point mutation (R225Q) on the AMPKγ3 subunit has been shown to activate the kinase 
and confers metabolic improvements in a high-fat diet model of insulin resistance 
(Barnes et al. 2004). Study III addressed whether skeletal muscle expression of 
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AMPKγ3
R225Q
 can confer metabolic improvements in a leptin deficient ob/ob mouse 
model of insulin resistance. 
 
4.3.2 AMPK γ3R225Q increases skeletal muscle glycogen content 
Skeletal muscle glycogen content in gastrocnemius was increased in lean transgenic 
γ3
R225Q
 mice (p<0.05 vs. WT mice). This result is consistent with reported effects of 
this (R225Q) and similar mutation (RN
-
 pig, R200Q), (humans, R225W) on skeletal 
muscle glycogen content (Milan et al. 2000; Barnes et al. 2004; Costford et al. 2007). 
Several mechanisms can be attributed to the increased glycogen content associated with 
AMPK activation. Acute activation of AMPK phosphorylates and thereby inhibits GS 
activity (Miyamoto et al. 2007) and this could lead to reduced glycogen content. 
AMPK activation also increases glucose uptake (Krook et al. 2004), with a concomitant 
increase in glucose-6-phosphate level, which allosterically overrides the inhibition 
imposed by AMPK on GS (Luptak et al. 2007; Hunter et al. 2011) thereby increasing 
glycogen synthesis (Study III, Fig 1). Defects in skeletal muscle glucose uptake and 
glycogen synthesis contribute to impairments in whole-body glucose metabolism in 
type 2 diabetic patients (Shulman et al. 1990; Zierath et al. 1998). Therefore, targeting 
skeletal muscle specific activation of the AMPKγ3 subunit can potentially improve 
glucose metabolism in metabolically dysregulated condition as in diabetes and obesity. 
 
4.3.3 Effect of AMPKγ3R225Q mutation on lipid oxidation and 
mitochondrial respiration 
Palmitate oxidation in EDL muscle from γ3
R225Q
 mice tended to be increased (p=0.06 
vs. WT). Previously, oleate oxidation was shown to be increased in EDL muscle from 
γ3
R225Q
 mice fed high fat diet and unaltered in muscle from mice fed a normal chow 
diet (Barnes et al. 2004). Activation of AMPK is associated with increase in lipid 
oxidation. This is a net result of ACC phosphorylation and inhibition by AMPK, 
leading to decreased malonyl-CoA levels, that negatively regulates CPT1 activity. 
Therefore, by decreasing malonyl-CoA levels, AMPK increases mitochondrial β-
oxidation (Winder et al. 1997). Glycogen content negatively regulates AMPK activity 
and hence lipid oxidation in skeletal muscle (Wojtaszewski et al. 2003; Steinberg et al. 
2006). Therefore, the γ3
R225Q
 mutation conferring increased glycogen content might 
prevent an increase in basal lipid oxidation during the palmitate oxidation experiments. 
The increased lipid oxidation in EDL muscle from γ3
R225Q
 mice fed a high fat diet 
(Barnes et al. 2004) could imply that hyperleptinemia associated with high fat feeding 
(Ahren et al. 1997) augments the effect of the γ3
R225Q
 mutation on lipid oxidation.  
 
Mitochondrial respiration was analyzed in permeabilized EDL muscles. Consistent 
with palmitate oxidation, mitochondrial respiration in EDL muscle fibers was similar 
between WT and γ3
R225Q 
mice (Study III, Fig 4). The AMPKγ3
R225Q
 mutation was 
reported to increase mitochondrial biogenesis, but not mitochondrial respiration 
(Garcia-Roves et al. 2008). Increased mitochondrial biogenesis is expected to increase 
mitochondrial respiration. The discordance between mitochondrial biogenesis and 
mitochondrial respiration could be due to the normalization method used in the 
respiration experiment. As mentioned earlier, glycogen content was higher in EDL 
muscle from γ3
R225Q
 mice and therefore water content of the skeletal muscle was likely 
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to be increased (MacKay et al. 1932). Consequently, when normalizing respiration data 
with respect to muscle weight, the γ3
R225Q
 mutant EDL muscle might have effectively 
less proteins and mitochondrial complexes. This could influence the final readout of the 
mitochondrial respiration data.  
 
4.3.4 AMPK activation and obesity 
Obesity and type 2 diabetes affect energy metabolism in insulin-sensitive tissues (liver, 
adipose tissue and skeletal muscle). Changes in energy metabolism may subsequently 
lead to defects in glucose and lipid metabolism. In the liver, metabolic dysregulation 
increases triglyceride content and glucose production (Murthy et al. 1979; DeFronzo et 
al. 1982; DeFronzo et al. 1985). The ability of insulin to suppress lipolysis from 
adipocytes is diminished in obesity (Hickner et al. 1999). Defective glucose uptake and 
glycogen synthesis in skeletal muscle is a hallmark of type 2 diabetes (Shulman et al. 
1990; Zierath et al. 1998). AMPK activation can overcome several of the metabolic 
disturbances in insulin sensitive tissues. AMPK activation in hepatic tissues improved 
lipid and glucose metabolism (Brusq et al. 2006; Cool et al. 2006) where as in 
adipocytes, lipolysis is reduced and lipogenesis is inhibited (Sullivan et al. 1994). 
AMPK activation in skeletal muscle increases glucose uptake and glycogen synthesis, 
with a concomitant increase in fatty acid oxidation (Merrill et al. 1997; Hunter et al. 
2011). Thus, targeting AMPK sensitive pathways may offer a potential therapeutic 
strategy to ameliorate metabolic abnormalities associated with type 2 diabetes and 
obesity.  
 
Skeletal muscle accounts for the majority of insulin-stimulated glucose uptake under 
fed conditions (DeFronzo et al. 1982; DeFronzo et al. 1985). Whole body insulin-
mediated glucose uptake is decreased in insulin resistant and type 2 diabetic patients. 
Defective insulin-stimulated GLUT4 translocation can account for reduced glucose 
uptake in type 2 diabetes (Kahn et al. 1991; Kahn et al. 1992). Signaling defects at 
multiple levels in the insulin signaling cascade have been implicated in defective 
GLUT4 translocation to cell surface (Björnholm et al. 1997; Vind et al. 2011). 
Pharmacological and physiological approaches that activate AMPK improve glucose 
uptake through increased GLUT4 levels and increased insulin-stimulated glucose 
uptake (Kurth-Kraczek et al. 1999; Musi et al. 2001; Koistinen et al. 2003; O'Gorman 
et al. 2006; Vind et al. 2011). Besides the above mentioned approaches, certain 
mutations associated with AMPKγ3 subunit results in increased glucose uptake and 
skeletal muscle glycogen content (Milan et al. 2000; Barnes et al. 2004; Costford et al. 
2007). Furthermore, humans bearing the AMPKγ3
R225W
 mutation in skeletal muscle 
had higher mitochondrial content, oxidative capacity, glucose uptake, and glycogen 
synthesis rates and reduced intramuscular triglyceride levels (Costford et al. 2007; 
Crawford et al. 2010). These studies highlight the important role of AMPK in 
regulating glucose homeostasis even in situations of metabolic perturbations as in type 
2 diabetes and obesity. 
 
Increased intramuscular triglyceride content is negatively correlated with skeletal 
muscle insulin sensitivity in sedentary and obese individuals (Sinha et al. 2002). 
AMPK activation enhances lipid metabolism in skeletal muscle (Merrill et al. 1997). 
From a molecular view point, AMPK activation leads to the phosphorylation and 
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subsequent inactivation of ACC (Kudo et al. 1996; Hutber et al. 1997), which leads to a 
decrease in malonyl-CoA synthesis. Malonyl-CoA, by negatively regulating 
mitochondrial CPT1 activity, results in reduced β-oxidation (McGarry et al. 1983; 
Rasmussen et al. 2002), with a subsequent increase in long chain acyl-CoA and 
triglyceride synthesis. Thus by inhibiting ACC, AMPK activation increases β-
oxidation. AMPK activation also increases mitochondrial biogenesis (Garcia-Roves et 
al. 2008; Crawford et al. 2010; Koltai et al. 2012; Price et al. 2012) which, when 
combined with increased β-oxidation augments the depletion of intramuscular 
triglyceride stores. Thus activation of AMPK by various means offers a metabolically 
favorable effect on glucose and lipid metabolism. Pathways mediated by AMPK can be 
targeted to improve insulin sensitivity in metabolically dysregulated conditions as in 
obesity and type 2 diabetes. 
 
Leptin activates AMPK in skeletal muscle by direct and indirect mechanisms 
(Minokoshi et al. 2002). AMPK activation by leptin subsequently leads to increase in 
lipid oxidation. Leptin also has a peripheral effect to increase skeletal muscle glucose 
uptake (Kamohara et al. 1997). This has potential therapeutic implications for common 
forms of obesity, which is associated with leptin resistance rather than leptin deficiency 
(Frederich et al. 1995). Leptin resistance is associated with lower basal metabolic rate 
and reduced glucose oxidation (Niskanen et al. 1997), which in turn leads to further 
weight gain. Further studies are required to address whether AMPK signaling is 
affected by leptin resistance. Whether activating AMPK in the presence of leptin 
resistance can confer leptin sensitivity and thereby improving insulin sensitivity also 
remains to be elucidated. Studies using a combination of peripheral leptin sensitizers 
and peripheral AMPK activators might open up new therapeutic strategies in the 
context of obesity and leptin resistance. 
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Figure 10: Regulation of whole-body energy metabolism by LepRb and AMPK signaling. 
Mutation of LepRb-Tyr985 enhances whole-body insulin sensitivity. The AMPKγ3
R225Q
 
mutation increases skeletal muscle glycogen content and decreases triglyceride content. Short-
term leptin treatment reduced hepatic and skeletal muscle triglyceride content in leptin deficient 
mice. 
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4.4 SUMMARY 
 The leptin receptor plays a prominent role in the regulation of hepatic and 
peripheral glucose metabolism. Attenuation of SOCS3-mediated feedback on 
LepRb-Tyr985 improves insulin-mediated suppression of hepatic glucose 
production. Enhanced leptin sensitivity conferred by this mechanism also improves 
whole body insulin sensitivity. Strategies that can reduce SOCS3 binding at LepRb-
Tyr985 may offer a potential approach to improve leptin resistance and thereby 
enhance hepatic and peripheral insulin sensitivity in the context of obesity and 
insulin resistance. 
 
 Metabolic perturbations as in the leptin-deficient obese condition bring about 
tissue-specific programming of mitochondrial function and dynamics. Hepatic 
mitochondrial function is impaired in the absence of functional leptin action and is 
not improved by short-term leptin treatment. Obesity-associated changes in 
glycolytic skeletal muscle increase mitochondrial electron transport capacity. 
Oxidative soleus muscle exhibits robust mitochondrial respiration, which is 
unaltered by either obesity or short-term leptin treatment. Understanding the 
molecular mechanisms behind these tissue-specific mitochondrial adaptations may 
bridge the gap between mitochondrial function and insulin resistance, and may pave 
the way for new treatments to improve insulin sensitivity. 
 
 AMPK activation by the γ3
R225Q
 mutation increases skeletal muscle glycogen 
content and increases skeletal muscle glucose uptake in lean insulin-sensitive mice. 
The same AMPK mutation imposes a metabolically favorable milieu (increased 
skeletal muscle glycogen content and reduced intramuscular triglyceride) in insulin 
resistant and obese ob/ob mice. Nevertheless, these metabolic adaptations were 
insufficient to ameliorate the whole-body metabolic disturbances arising from the 
life-long leptin-deficiency. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
The overall aim of this thesis was to investigate the role of central and peripheral 
mechanisms regulating energy and glucose homeostasis. To address this issue, two 
pathways were studied: 1) leptin receptor-mediated signaling, 2) AMPK-mediated 
signaling. These signaling pathways were put in the context of insulin sensitivity and 
energy homeostasis. 
 
Studies in this thesis highlight the role of leptin receptor and AMPK signaling in the 
regulation of whole-body insulin sensitivity. Furthermore, the effect of leptin treatment 
on tissue-specific mitochondrial function is evaluated in the context of metabolic 
disturbances associated with obesity. Results from Study I provide evidence for a role 
of LepRb-Tyr985 in the regulation of hepatic glucose production and peripheral insulin 
sensitivity. Binding of the negative regulator, SOCS3 to the LepRb is blocked when 
Tyr985 on LepRb is mutated to Leu985 (Bjorbaek et al. 2000). Reduced binding of 
SOCS3 on LepRb increases leptin sensitivity (Björnholm et al. 2007) and thereby 
enhances hepatic and peripheral insulin sensitivity, implying strategies to improve 
leptin sensitivity may also increase whole-body insulin sensitivity. This has therapeutic 
potential that can be utilized to address the leptin resistance observed in the common 
forms of obesity. Study I, while highlighting an important role for LepRb-Tyr985 in 
mediating whole-body insulin sensitivity, has not identified the insulin-sensitive tissues 
responsible for mediating these actions. Future research should therefore be aimed at 
identifying the tissue-specific effects of LepRb-Tyr985 mutation in mediating whole-
body insulin sensitivity. Furthermore, additional studies to explore the beneficial effects 
of the LepRb-Tyr985 mutation in preventing leptin resistance and improving whole-
body insulin sensitivity in a mouse model of leptin resistance and insulin resistance 
(high fat diet studies) should be performed. 
 
Mitochondrial respiration studies of isolated tissues from ob/ob mice indicate that 
tissue-specific alterations in mitochondrial function occur in the context of obesity. In 
glycolytic skeletal muscle mitochondrial respiration is increased in obesity, whereas in 
oxidative soleus muscle mitochondrial respiratory capacity is unaltered and 
unresponsive to leptin treatment. Hepatic mitochondrial capacity is negatively affected 
by obesity, whereas short-term leptin treatment partially improves hepatic steatosis in 
the absence of further improvements in mitochondrial capacity. The present work 
evaluating tissue-specific mitochondrial respiration in ob/ob mice highlights a neutral 
role for short-term leptin treatment in correcting altered mitochondrial function in 
obesity. These results indicate that the improvement in whole body insulin sensitivity 
after short-term leptin treatment (Yaspelkis et al. 2001; Nagao et al. 2008; Denroche et 
al. 2011) is dissociated from changes in mitochondrial respiratory capacity. Diabetes 
and obesity are chronic metabolic disorders that require long-term treatment 
interventions. Therefore, further studies are warranted to address whether long-term 
leptin treatment affects tissue-specific mitochondrial function and whether leptin has an 
effect on mitochondrial function in leptin-sensitive tissues like adipocyte or brain. 
 
The effect of chronic AMPK activation (AMPKγ3
R225Q
)
 
to improve whole-body insulin 
sensitivity in leptin-deficiency remains incompletely resolved. Study III provides 
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evidence to suggest that skeletal muscle-specific AMPK activation improves insulin 
sensitivity in a tissue-specific manner and functional leptin action is required for this 
effect. The increased glycogen content in the gastrocnemius muscle from the leptin-
deficient ob/ob-γ3
R225Q
 mice indicates that leptin is not required for AMPK-mediated 
glycogen synthesis. Moreover, the effect of the AMPKγ3
R225Q
 mutation on glycogen 
content is independent of adiposity. Intramuscular triglyceride content is also reduced 
in ob/ob-γ3
R225Q
 transgenic mice, presumably due to decreased triglyceride synthesis, 
since basal lipid oxidation was unaltered. However, the improvements in muscle 
biochemistry arising from the AMPKγ3
R225Q
 mutation are insufficient to ameliorate 
whole-body insulin resistance in the leptin-deficient mice. Consequently, a 
permissive amount of leptin may be required to fully confer the AMPKγ3
R225Q
-
dependent improvements in skeletal muscle insulin-sensitivity. Thus, lack of central 
leptin signaling in ob/ob mice may override the favorable metabolic milieu conferred 
by peripheral expression of the AMPKγ3
R225Q
 mutation to improve glucose and energy 
homeostasis. The present study underscores the role of leptin in mediating whole-body 
insulin sensitivity in a metabolically challenged situation as in ob/ob mice.  
 
Collectively, the studies presented in this thesis highlight the role of two important 
signaling pathways in the regulation of various aspects of glucose and lipid metabolism 
from a whole body perspective. The leptin and AMPK signaling pathways were 
explored to determine their beneficial effects in the context of insulin resistance. 
Treatment strategies targeted at improving leptin sensitivity and skeletal muscle insulin 
sensitivity via AMPK signaling may provide new opportunities for the treatment of 
metabolic complications associated with diabetes and obesity.  
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